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SUMMARY 
 
The aminocoumarin antibiotics novobiocin, clorobiocin and coumermycin A1 are 
potent inhibitors of DNA gyrase and are produced by different Streptomyces strains. 
Cloning and sequencing of the corresponding biosynthetic gene clusters allowed 
detailed investigations of their biosynthetic pathways in recent years and now the 
functions of nearly all genes in biosynthesis, regulation and resistance are known. 
 
In the first part of this thesis the production of novobiocin was investigated in 24-
square deepwell plates, an alternative cultivation system to Erlenmeyer flasks. 
Investigations on antibiotic production are often hampered by the notorious variability 
of production rates observed in Erlenmeyer flasks, even between parallel cultivation 
batches of the same strain. The high standard deviation in the production rates 
makes it necessary to increase the number of parallel cultures if significant 
differences need to be distinguished from chance variations. Therefore a cultivation 
method which shows less variability in secondary metabolite production could 
significantly reduce the workload and cost of research in antibiotic biosynthesis. 
Comparison of novobiocin production in Erlenmeyer flasks and 24-square deepwell 
plates showed that the production was originally higher in the Erlenmeyer flasks (24 
mg/L vs. 11 mg/L). However, the variability was much lower in the deepwell plate (SD 
6% vs. 39%). Optimization of the inoculation ratio and preparation of frozen inoculum 
from a defined section of the growth phase further reduced the variability, especially 
between independent cultivation batches (SD 6% vs. 52%). Addition of the water 
soluble siloxylated ethylene oxide/propylene oxide copolymer Q2-5247, as artificial 
oxygen carrier, as well as the overexpression of the pathway-specific positive 
regulator NovG increased novobiocin production to levels comparable to those in the 
Erlenmeyer flasks (54 mg/L and 48 mg/L, respectively). Combination of the positive 
effects of NovG and of copolymer Q2-5247 led to a novobiocin production of 163 
mg/L, exceeding all previous production levels observed in Erlenmeyer flasks in our 
laboratory. 
 
For the production of coumermycin A1 in the 24-square deepwell plates, two 
alternative production media were tested because the originally used SK medium 
was not suitable, due to the contained lard oil. In the first medium, a coumermycin 
production of 17 mg/L was observed. However, the main product was not 
coumermycin A1 but coumermycin C, which lacks one of the terminal pyrrole 
moieties. In the second medium coumermycin production was not only higher (53 
mg/L) than in the first medium, but coumermycin A1 was now the main product. 
Therefore, the second medium was chosen for all further experiments.   
 
 
Coumermycin A1 contains two types of pyrrole moieties, two terminal 5-
methylpyrrole-2-carboxylic acid moieties and the central 3-methylpyrrole-2,4-
dicarboxylic acid moiety. The terminal pyrrole moiety is also present in clorobiocin 
and its biosynthesis from L-proline by action of CouN1-7 is well investigated. 
However, the biosynthetic precursors of the central pyrrole moiety have remained 
unknown, and none of the genes or enzymes involved in its formation have been 
identified so far. In the second part of this thesis evidence is provided that five genes, 
termed couR1-couR4, contained in a contiguous 4.7 kb region within the 
 SUMMARY XI 
 
coumermycin biosynthetic gene cluster, are required for the biosynthesis of the 
central pyrrole moiety. Each of these genes was deleted individually, resulting in a 
strong reduction (by at least 92%) or an abolishment of coumermycin production. 
External feeding of the central pyrrole moiety, i.e. 3-methylpyrrole-2,4-dicarboxylic 
acid, restored coumermycin production. One of the enzymes involved, i.e. CouR3, 
shows similarity to the L-threonine kinase PduX from Salmonella enterica, and 
feeding of O-phospho-L-threonine to a couR3 defective mutant resulted in a 
moderate increase of coumermycin production, while feeding of L-threonine (0.197 
mg/L vs. 0.143 mg/L) did not, indicating that the first step in the biosynthesis might be 
the phosphorylation of L-threonine. Feeding of [U-13C,15N]L-threonine and 13C NMR 
analysis of the resulting labeled CPM monoamide unequivocally proved that 
threonine is incorporated intact into the central pyrrole moiety (19 % enrichment), 
providing the heterocyclic nitrogen as well as four of the seven carbons of this 
moiety. Therefore, the central pyrrole moiety is formed via a new, hitherto unknown 
biosynthetic pathway. A hypothesis for the reaction sequence leading to this moiety, 
starting from L-threonine and oxaloacetate, is presented. A second feeding 
experiment with [U-13C]fumaric acid did not show significant incorporation.  
 
 
Caprazamycins are potent anti-mycobacterial liponucleoside antibiotics that belong to 
the translocase I inhibitors and are produced by Streptomyces sp. MK730-62F2. 
Their complex structure is derived from 5‟-(β-O-aminoribosyl)-glycyluridine and 
comprises a unique N-methyl-diazepanone ring. Recently, the caprazamycin 
biosynthetic gene cluster was identified by our group. 
 
In the third part of the presented thesis, a liquid chromatography/electrospray 
ionization tandem mass spectrometry (LC/ESI-MS/MS) method is reported for the 
structural elucidation of caprazamycins and liposidomycins from culture extracts of 
the respective producer strains. Both caprazamycins and liposidomycins were readily 
detected in positive as well as in negative ionization mode and the comparison of the 
fragmentation pattern revealed several characteristic product ions. These product 
ions can be divided into two groups, according to whether they still contain the fatty 
acid side chain or not. Those that lack the fatty acid side chain are characteristic for 
all caprazamycins and/or liposidomycins, respectively, and were used for the 
identification of six new caprazamycins that probably contain unsaturated fatty acid 
side chains. The proposed chemical formula of these new compounds fit that of the 
fatty acid moieties of the liposidomycins Y, Z, A, G, K and N, respectively. On the 
whole, the positive ionization mode provided more structural information, while the 
negative ionization mode seems to be of advantage if informations regarding the 
sulfate group or the fatty acid side chains are required.  
 
A chromatographic method using a boronic acid stationary phase, which was 
originally used for the purification of modified nucleosides from cell cultures, was 
adapted for the partial purification of the culture extracts. The fractions containing the 
caprazamycins were identified by a bioactivity assay with Mycobacterium phlei and 
by LC-MS/MS analysis, respectively. To prevent an early elution of the compounds, 
the methanol content in the second washing step needed to be reduced from 50% to 
20%. 
 
XII ZUSAMMENFASSUNG   
 
ZUSAMMENFASSUNG 
 
Die Aminocoumarin-Antibiotika Novobiocin, Clorobiocin und Coumermycin A1 sind 
potente Inhibitoren der DNA-Gyrase und werden von verschiedenen Streptomyceten 
gebildet. Die Klonierung und Sequenzierung der entsprechenden Biosynthese-
gencluster ermöglichte in den letzten Jahren eine detaillierte Untersuchung ihrer 
Biosynthesewege und die Funktion fast aller Gene in Biosynthese, Regulation und 
Resistenz ist mittlerweile bekannt. 
 
Im ersten Teil dieser Arbeit wurde die Produktion von Novobiocin in 24-Kammer-
Platten untersucht, welche ein alternatives Kultivierungssystem zu Erlenmeyerkolben 
darstellen. Untersuchungen zur Antibiotikaproduktion in Streptomyceten werden oft 
durch die stark schwankenden Produktionsraten in Erlenmeyerkolben behindert, 
welche man selbst zwischen parallel angezogenen Kulturen ein und desselben 
Stammes beobachten kann. Die großen Standardabweichungen machen es daher 
oft nötig viele parallele Kultivierungen durchzuführen wenn man echte Unterschiede 
in den Produktionsraten von zufälligen Schwankungen unterscheiden will. Aus 
diesem Grund könnte eine Kultivierungsmethode, welche geringere Schwankungen 
in den Produktionsraten aufweist, den Arbeitsaufwand und die Kosten in der 
Antibiotikaforschung deutlich reduzieren. Ein Vergleich der Novobiocinproduktion in 
Erlenmeyerkolben und einer 24-Kammer-Platte ergab zunächst eine deutlich höhere 
Produktion im Erlenmeyerkolben (24 mg/L vs. 11 mg/L). Die Kulturen aus der 24-
Kammer-Platte wiesen im Vergleich zu denen aus dem Erlenmeyerkolben allerdings 
deutlich geringere Produktionsschwankungen auf (Standardabweichung: 6% vs. 
39%). Durch die Optimierung des Animpfverhältnisses sowie die Herstellung von 
eingefrorenem Inoculum aus Vorkulturen in der Wachstumsphase, konnte eine 
weiteren Abnahme der Variabilität, besonders zwischen unabhängige Kultivierungen 
(Standardabweichung: 6% vs. 52%), erreicht werden. Der Zusatz eines 
wasserlöslichen Copolymers aus Ethylenoxid und Propylenoxid sowie die 
Überexpression des spezifischen positiven Regulators NovG führte jeweils zu 
vergleichbaren Produktionen wie im Erlenmeyerkolben (54 mg/L bzw. 48 mg/L). 
Diese positiven Effekte von Copolymer-Zusatz und NovG-Überexpression lassen 
sich auch kombinieren, sodass schließlich eine Novobiocinproduktion von 163 mg/L 
erreicht werden konnte, was alle bisher von uns beobachteten Produktionsraten im 
Erlenmeyerkolben deutlich übersteigt. 
 
Für die Produktion von Coumermycin A1 in den 24-Kammer-Platten wurden zwei 
alternative Produktionsmedien getestet, weil das ursprüngliche verwendete SK-
Medium aufgrund des enthaltenen Fettes leider ungeeignet war. In dem ersten 
getesteten Medium ergab sich eine Gesamtproduktion von 17 mg/L. Das 
Hauptprodukt war in diesem Fall allerdings nicht Coumermycin A1 sondern 
Coumermycin C, welchem eine der beiden endständigen Pyrroleinheiten fehlt. Im 
zweiten Medium fiel die Produktion dann nicht nur deutlich höher aus (53 mg/L), 
sondern Coumermycin A1 war diesmal auch das Hauptprodukt. Aus diesem Grund 
wurde entschieden das zweite Medium für alle weiteren Versuche zu verwenden. 
 
 
 
 ZUSAMMENFASSUNG XIII 
 
Coumermycin A1 enthält zwei verschiedene Pyrroleinheiten, die beiden endständigen 
5-Methylpyrrol-2-carbonsäure-Einheiten und die zentrale 3-Methylpyrrol-2,4-di-
carbonsäure. Die endständige Pyrroleinheit findet sich auch im Clorobiocin wieder 
und ihre Biosynthese, ausgehend von L-Prolin und katalysiert durch CouN1-7, ist gut 
untersucht. Die Biosynthesevorstufen der zentralen Pyrroleinheit, andererseits, sind 
noch vollkommen unbekannt und keines der beteiligten Gene oder Enzyme wurden 
bisher identifiziert. Der zweite Teil dieser Arbeit erbringt nun den Nachweis, dass fünf 
Gene, couR1-couR4, die sich in einem 4,7 kb großen Abschnitt innerhalb des 
Coumermycin-Genclusters befinden, für die Biosynthese der zentralen Pyrroleinheit 
verantwortlich sind. Jedes dieser Gene wurde einzeln inaktiviert, was zu einer 
starken Reduzierung (wenigstens 92%) oder sogar zum Ausfall der Coumermycin-
produktion führte. Durch Fütterung der zentralen Pyrroleinheit, 3-Methylpyrrol-2,4-
dicarbonsäure, konnte die Produktion dann teilweise wiederhergestellt werden. Eines 
der beteiligten Enzyme, und zwar CouR3, zeigt Ähnlichkeit zu der Threoninkinase 
PduX aus Salmonella enterica und die Fütterung von O-Phospho-L-Threonin zu einer 
couR3-defekten Mutante führte zu einer leichten Produktionssteigerung im Vergleich 
zur Fütterung von L-Threonin (0,197 mg/L vs. 0,143 mg/L). Dies deutet darauf hin, 
dass der erste Schritt in der Biosynthese der zentralen Pyrroleinheit womöglich in der 
Phosphorylierung von L-Threonin besteht. Die Fütterung von [U-13C,15N]L-Threonin 
und die anschließende 13C NMR-Analyse des resultierenden gelabelten Monoamids 
der zentralen Pyrroleinheit zeigen eindeutig, dass das intakte Threonin in diese 
Einheit eingebaut wird (Anreicherung 19%) und dass es sowohl den heterozyklischen 
Stickstoff als auch vier der sieben Kohlenstoffatome liefert. Das bedeutet, dass die 
zentrale Pyrroleinheit von Coumermycin A1 über einen neuen, bisher vollkommen 
unbekannten, Biosyntheseweg gebildet wird. Eine Hypothese für den Ablauf dieser 
Biosynthese, ausgehend von Threonin und Oxalacetat, wurde aufgestellt. Leider war 
ein zweiter Fütterungsversuch, diesmal mit [U-13C]Fumarsäure, nicht erfolgreich. 
 
 
Caprazamycine sind Liponukleosid-Antibiotika und werden zu den Translokase I-
Inhibitoren gezählt. Sie werden von Streptomyces sp. MK730-62F2 produziert und 
weisen eine sehr gute Wirksamkeit gegen Mykobakterien und anderen grampositive 
Mikroorganismen auf. Die Caprazamycine besitzen eine hochkomplexe chemische 
Struktur, bestehend aus einem 5‟-(β-O-Aminoribosyl)-Glycyluridin und einem N-
Methyl-Diazepanonring. Das entsprechende Biosynthesegencluster wurde erst 
kürzlich in unserem Arbeitskreis identifiziert. 
 
Im dritten Teil dieser Arbeit wird eine HPLC/ESI-MS/MS-Methode für die 
Identifizierung von Caprazamycinen und Liposidomycinen, in Kulturextrakten der 
jeweiligen Produktionsstämme, vorgestellt. Beide Verbindungsklassen konnten 
sowohl bei positiver als auch bei negativer Ionisierung eindeutig identifiziert werden 
und der Vergleich der Fragmentierungsmuster zeigte mehrer charakteristische 
Produktionen.  Diese lassen sich in zwei Klassen einteilen, je nachdem ob sie noch 
die Fettsäure-Seitenkette enthalten oder nicht. Produktionen denen die Fettsäure 
fehlt, sind charakteristisch für alle Caprazamycine bzw. Liposidomycine, und wurden 
daher für die Identifizierung von insgesamt sechs neuen Caprazamycinen 
herangezogen, welche wahrscheinlich ein- und zweifach ungesättigte Fettsäuren 
enthalten. Die vorgeschlagenen Summenformeln der neuen Verbindungen passen 
jeweils zu den Fettsäuren der Liposidomycine Y, Z, A, G, K und N. Insgesamt liefern 
die Spektren bei positiver Ionisierung mehr Strukturinformation, aber die negative 
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Ionisierung könnte immer dann von Vorteil sein, wenn Informationen bezüglich der 
Sulfatgruppe oder der Fettsäure benötigt werden. 
 
Eine chromatographische Methode unter Verwendung eines Boronsäure-Gels, 
welche ursprünglich für die Aufreinigung von modifizierten Nukleosiden aus 
Zellkulturen verwendet wurde, wurde für die teilweise Aufreinigung der Kulturextrakte 
angepasst. Die Fraktion, welche die Caprazamycine enthält, wurde anschließend 
mittels eines Bioaktivitäts-Assays mit Mycobacterium phlei sowie mittels HPLC-
MS/MS identifiziert. Um ein vorzeitiges Eluieren der Substanzen zu verhindern, war 
es nötig den Methanolgehalt im zweiten Waschschritt von 50% auf 20% zu 
reduzieren. 
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1. Antibiotic resistance and the need for new antibiotics 
 
Infectious diseases continue to be a major health problem (Watve et al., 2001), 
mainly due to the increasing prevalence of antibiotic resistance in pathogenic 
bacteria in hospitals and in the community (Fischbach & Walsh, 2009). 
 
Penicillin-resistant Staphylococcus aureus emerged soon after the introduction of 
penicillin in the 1940s and by 1986 methicillin-resistant S. aureus (MRSA) became so 
prevalent that vancomycin became a front-line antibiotic in the treatment of MRSA 
infections. Since then, MRSA have evolved to vancomycin-resistant S. aureus 
(VRSA) (Walsh, 2003). In the developing world, multidrug-resistant (MDR) and 
extensively-drug-resistant (XDR) strains of Mycobacterium tuberculosis are an 
increasing problem (Fischbach & Walsh, 2009), especially in co-infections with HIV, 
since the risk of developing active tuberculosis is increased (Ma et al., 2010). 
Furthermore, rifampicin, a first-line drug in tuberculosis treatment, renders protease 
inhibitors ineffective due to the induction of CYP3A4 and p-glycoprotein expression 
(Ma et al., 2010). The emergence of multidrug-resistant Gram-negative pathogens, 
especially in intensive care units, is another serious problem. Some Entero-
bacteriaceae, like Enterobacter and Klebsiella, carry extended-spectrum β-
lactamases, which are able to destroy even the latest generations of penicillins and 
cephalosporins and the metallo-β-lactamases can even inactivate carbapenems, 
often the “last resort” in infections caused by Gram-negative bacteria (Levy & 
Marshall, 2004). Furthermore, Pseudomonas aeruginosa and Acinetobacter 
baumannii are sometimes resistant to all antibiotics (Levy & Marshall, 2004).  
 
 
1936 1940 1949 1950 1952 1958 1962 2000
Sulfa drugs
Phenyl propanoids
Polyketides Macrolides Quinolones Streptogramins
β-Lactams Aminoglycosides Glycopeptides Oxazolidinones
 
 
Figure I.1  
Introduction of new classes of antibiotics into clinical practice between 1936 and 2000. 
Modified from Walsh (2003). 
 
 
The use of antibiotics inevitably selects for resistant microbes, and therefore there is 
a continuing and cyclical need for new and more effective antibiotics (Clardy et al., 
2006). However, progress in developing them has been slow and only three new 
classes of antibiotics have been introduced in the past 50 years: the quinolones, the 
streptogramins and the oxazolidinones (Figure I.1) (Fischbach & Walsh, 2009; 
Walsh, 2003). Among the 15 antibiotics currently in the pipeline are three cephalo-
2 I. INTRODUCTION   
 
sporins, three glycopeptides and four quinolones, but not one representative of a new 
antibiotic class and especially the lack of new antibiotics against Gram-negative 
bacteria is concerning (Freire-Moran et al., 2011; Schmitz & Holzgrabe, 2011). 
 
Natural products are among the most important sources for new drug candidates 
(Kumar & Waldmann, 2009), though structural modifications of these compounds are 
often necessary to optimize the pharmacological properties and to minimize toxicity 
(Baltz, 2008). More than 60% of the antibacterial and anticancer drugs introduced 
between 1981 and 2002 originated from natural sources (Lam, 2007), mostly from 
actinomycetes or fungi (Baltz, 2007). Despite the success of natural products as 
sources of new drug leads, many pharmaceutical companies terminated their natural 
product research programs, focusing now on combinatorial chemistry and high-
throughput, target-based screening of synthetic compound libraries (Baltz, 2007; 
Lam, 2007; Li & Vederas, 2009). However, the structural diversity of natural products 
is still unmatched (Lam, 2007) and significant progress in the areas of genome 
sequencing, bioinformatics, genetic engineering and analytical chemistry, the 
development of new screening methods and the access to so far unexplored 
microbial niches, will hopefully renew the interest in natural product research (Baltz, 
2008; Clardy et al., 2006; Fischbach & Walsh, 2009; Lam, 2007; Li & Vederas, 2009). 
 
 
2. Aminocoumarin antibiotics 
 
The aminocoumarin antibiotics novobiocin, clorobiocin and coumermycin A1 are 
produced by different Streptomyces strains, e.g. novobiocin by S. spheroides (syn. S. 
caeruleus) NCIMB 11891 (Lanoot et al., 2002; Steffensky et al., 2000), clorobiocin by 
S. roseochromogenes var. oscitans DS12.976 (Mancy et al., 1974) and coumermycin 
A1 by S. rishiriensis (Kawaguchi et al., 1965; Weinstein et al., 1978). The more 
recently discovered simocylinone D8 (Schimana et al., 2000) and rubradirin (Sohng 
et al., 1997), which are structurally more complex than the three “classical” 
aminocoumarin antibiotics, are also produced by different Streptomyces strains. 
 
2.1. Chemical structure 
 
The aminocoumarin antibiotics are characterized by their 3-amino-4,7-dihydroxy-
coumarin moiety, which is attached to an acyl component via an amide bond and to 
an deoxysugar moiety, i.e. 4-O-methyl-5-C-methyl-L-rhamnose, via a glycosidic bond. 
Novobiocin and clorobiocin share the same acyl component, i.e. 3-dimethylallyl-4-
hydroxybenzoate, while coumermycin A1 contains a 3-methylpyrrole-2,4-dicarboxylic 
acid moiety (central pyrrole moiety). The same aminocoumarin-deoxysugar moiety is 
attached in coumermycin A1 to both carboxyl groups of the central pyrrole moiety, 
leading to a nearly symmetric molecule. The 3-OH group of the deoxysugar moiety is 
acylated in all three aminocoumarin antibiotics, either with a carbamyl group 
(novobiocin) or with a 5-methylpyrrole-2-carboxyl group (clorobiocin and 
coumermycin A1). As suggested by the name, clorobiocin contains a chlorine atom at 
position 8 of the aminocoumarin moiety, whereas novobiocin and coumermycin A1 
carry a methyl group at the same position (Figure I.2).  
 
 I. INTRODUCTION 3 
 
Simocylinone D8 and rubradirin share the 3-amino-4,7-dihydroxycoumarin moiety 
with the “classical” aminocoumarins, but their acyl components are structurally more 
complex and they contain different deoxysugar moieties, which are attached to the 
acyl moiety rather than to the aminocoumarin ring (Figure I.2). 
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Figure I.2 
Chemical structures of the aminocoumarin antibiotics 
 
 
2.2. Biosynthetic gene clusters 
 
The novobiocin biosynthetic gene cluster was the first gene cluster of an 
aminocoumarin antibiotic that was cloned and sequenced (Steffensky et al., 2000). 
Subsequently, the gene clusters of coumermycin A1 (Wang et al., 2000) and 
clorobiocin (Pojer et al., 2002) followed. The clusters span between 23 and 38 kb and 
comprise between 20 and 32 coding sequences (Heide, 2009). Nearly all the genes 
have been investigated by genetic and biochemical methods and their functions in 
biosynthesis, regulation and resistance are known (Heide, 2009). Although the 
structural differences between the three antibiotics are well reflected by the 
differences in the gene clusters (Li & Heide, 2006), the genes responsible for the 
biosynthesis of a certain moiety, e.g. for the biosynthesis of the aminocoumarin 
moiety, have the same order in all three clusters and show high sequence similarity 
(Figure I.3).  
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All three gene clusters contain two positive regulators e.g. novE and novG in the 
novobiocin gene cluster (Dangel et al., 2008; Eustáquio et al., 2005; Eustáquio et al., 
2003), as well as a gene coding for an aminocoumarin-resistant gyrase B subunit, 
termed gyrBR (Schmutz et al., 2003a; Steffensky et al., 2000). The gene clusters of 
clorobiocin and coumermycin A1 additionally contain a gene immediately downstream 
of gyrBR which showed, on average, 44% identity and 57% similarity to gyrBR on the 
amino acid level. This gene, named parYR, codes for an aminocoumarin-resistant 
topoisomerase IV subunit and is not present in the novobiocin gene cluster (Schmutz 
et al., 2003a). 
 
The gene clusters of simocyclinone and rubradirin are larger and span approximately 
65 and 105 kb, respectively. Their precise borders are not defined yet (Heide, 2009). 
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Figure I.3  
The biosynthetic gene clusters of novobiocin (nov), clorobiocin (clo) and coumermycin A1 
(cou) 
 
 
2.3. Biosynthesis of coumermycin A1 
 
Coumermycin A1 consists of three structural moieties, i.e. the 3-amino-4,7-dihydroxy-
coumarin moiety, the central 3-methylpyrrole-2,4-dicarboxylic acid moiety and a 
substituted deoxysugar moiety (Figure I.2).  
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The genes couHIJK are responsible for the biosynthesis of the aminocoumarin 
moiety (Chen & Walsh, 2001; Pacholec et al., 2005a), which is derived from L-
tyrosine, as was demonstrated by feeding experiments with isotope-labeled 
precursors (Bunton et al., 1963). The small gene couY, which is located directly 
upstream of couH, shows sequence similarity to mbtH from the mycobactin gene 
cluster of Mycobacterium tuberculosis (Baltz, 2011; Quadri et al., 1998) and is 
probably involved in the adenylation of L-tyrosine catalyzed by CouH (Baltz, 2011; 
Wolpert et al., 2007; Zhang et al., 2010). The origin of the heterocyclic oxygen atom 
is yet unknown, although Bunton et al. (1963) provided evidence that it is derived 
from the carboxyl group of L-tyrosine. However, Holzenkämpfer and Zeeck (2002) 
later showed for simocyclinone that it originated from molecular oxygen, which 
contradicts the earlier finding. The position 8 of the aminocoumarin ring is methylated 
by the methyltransferase CouO (Figure I.4) (Pacholec et al., 2005b).  
 
The deoxysugar moiety, a 5-C-methyl-L-rhamnose, is derived from glucose-1-
phosphate and the additional methyl group at C-5 from S-adenosylmethionine (Birch 
et al., 1960). The genes responsible for the biosynthesis of this moiety are 
couSTUVW (Heide, 2009), which are located at the right border of the cluster (Figure 
I.3). The activated deoxysugar moiety is transferred to the 7-hydroxy group of the 
aminocoumarin ring by the glycosyl transferase CouM. Methylation of the 4-hydroxy 
group, which is catalyzed by CouP (Li et al., 2002), and acylation of the 3-hydroxy 
group with a 5-methylpyrrole-2-carboxylic acid moiety occur only after glycoside 
formation (Figure I.4) (Heide, 2009).  
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Figure I.4 
Structure of coumermycin A1 and function of the gene products of couHIJKLMNOPRSTUVW 
in coumermycin A1 biosynthesis 
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Coumermycin A1 contains three pyrrole moieties, i.e the central 3-methylpyrrole-2,4-
dicarboxylic acid moiety and two terminal 5-methylpyrrole-2-carboxylic acid moieties. 
The terminal pyrrole moieties, which are also present in clorobiocin, are derived from 
L-proline (Scannell & Kong, 1969).  In the first reaction step proline is activated by 
thioester formation with an acyl carrier protein and then subsequently oxidized to the 
pyrrole, methylated by a cobalamine-dependent methyltransferase and transferred to 
the deoxysugar moiety in a two-step acyl transfer process. This reaction sequence is 
catalyzed by the gene products of the seven genes couN1-7 (Balibar et al., 2007; 
Fridman et al., 2007; Garneau-Tsodikova et al., 2006; Garneau et al., 2005). 
However, these genes are not responsible for the biosynthesis of the central pyrrole 
moiety, which is derived from L-threonine rather than from L-proline, as demonstrated 
in this thesis. The genes responsible for the biosynthesis are couR1-4 (Figure I.4). 
The formation of the amide bonds between the central pyrrole moiety and the 
aminocoumarin moieties is catalyzed by the amide synthetase CouL (Schmutz et al., 
2003b). 
 
2.4. Mechanism of action and resistance 
 
Novobiocin, clorobiocin and coumermycin A1 are all potent inhibitors of the bacterial 
DNA gyrase (Maxwell, 1999) and show a considerably higher affinity for this enzyme 
than the fluoroquinolones (Maxwell & Lawson, 2003). However, the affinity of 
coumermycin A1 towards intact gyrase is higher than that of any other 
aminocoumarin antibiotic. A 50 % inhibition of gyrase was reported to occur at a 
concentration of 4 nM, in comparison to 100 nM for novobiocin (Peng & Marians, 
1993b). 
 
Bacterial DNA gyrase is a type II topoisomerase, which uniquely catalyses the 
negative supercoiling of closed-circular DNA using the free energy of ATP hydrolysis. 
Its unique presence in prokaryotes makes it an attractive drug target (Gormley et al., 
1996; Tsai et al., 1997). DNA gyrase is composed of two subunits, GyrA and GyrB, 
forming an A2B2 heterotetramer (Maxwell, 1999; Schmutz et al., 2004). GyrA is 
involved in the DNA breakage-resealing reactions while GyrB catalyzes ATP 
hydrolysis (Maxwell, 1999). Topoisomerase IV is another type II topoisomerase which 
is target by the aminocoumarin antibiotics (Peng & Marians, 1993b). Its primary role 
is the decatenation of daughter chromosomes following DNA replication. Like gyrase 
it consists of two subunits, ParC and ParE, forming a C2E2 heterotetramer, with ParE 
containing the nucleotide binding site and ParC being responsible for DNA breakage 
and reunion (Hardy & Cozzarelli, 2003; Peng & Marians, 1993a). 
 
Aminocoumarin antibiotics target the B subunit of gyrase and were shown to be 
competitive inhibitors of the ATP hydrolysis reaction, although they show little 
structural resemblance with ATP (Maxwell, 1993; Tsai et al., 1997). X-ray 
christallography studies with an 24 kDa N-terminal fragment of GyrB from 
Escherichia coli in complex with the non-hydrolysable ATP analogue ADPNP (5‟-
adenylyl-β,γ-imidodiphosphate), novobiocin (Lewis et al., 1996) and clorobiocin (Tsai 
et al., 1997), respectively, revealed that the deoxysugar moiety of the 
aminocoumarins overlaps with the binding site for the adenine ring of ATP. While the 
substituted deoxysugar and the aminocoumarin ring are essential for the inhibition of 
gyrase, the 3-dimethylallyl-4-hydroxybenzoate moiety is not required, though it may 
influence the uptake of the compounds into the cells (Maxwell & Lawson, 2003). The 
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novobiocin and clorobiocin binding site shows a network of hydrogen bonds and a 
number of hydrophobic interactions. Key hydrogen bonds are those between Arg136 
and the aminocoumarin ring, Asn46 and the 2-hydroxyl group of the deoxysugar 
moiety, and between Asp73 and the 3-acyl group of the deoxysugar moiety (Lewis et 
al., 1996; Maxwell & Lawson, 2003; Tsai et al., 1997). In contrast to novobiocin and 
clorobiocin, coumermycin A1 was shown to stabilize a dimer of a 43 kDa N-terminal 
fragment of GyrB, which is consistent with its pseudo-dimeric structure (Figure I.2) 
(Gormley et al., 1996; Maxwell & Lawson, 2003). 
 
Simocyclinone also is a potent inhibitor of DNA gyrase, although with a different 
mode of action. Instead of inhibiting the ATPase reaction of GyrB it prevents the 
binding of the enzyme to DNA (Flatman et al., 2005). Rubradirin is structurally related 
to the ansamycin family of antibiotics. Most members of this group act as potent 
inhibitors of the bacterial RNA polymerase (RNAP), e.g. the rifamycins. However, 
intact rubradirin was shown to inhibit the bacterial protein synthesis rather than 
RNAP, although its aglycone is a potent inhibitor of this enzyme (Reusser, 1979). 
 
Analysis of aminocoumarin-resistant bacterial strains from several species led to the 
identification of point mutations in the N-terminal domain of GyrB that cause 
aminocoumarin-resistance. The most frequently mutated residue was an arginine 
(Arg136 in E. coli GyrB), which was found to form a hydrogen bond with the 
aminocoumarin moiety (Maxwell, 1997; Maxwell & Lawson, 2003). The accumulation 
of mutations in both gyrB and parE was shown to be associated with high-level 
resistance to novobiocin in S. aureus. However, mutations in parE only occured in 
mutants that had previously acquired mutations in gyrB, indicating that gyrase is the 
primary target of novobiocin (Fujimoto-Nakamura et al., 2005). Another mechanism 
that contributes to bacterial antibiotic resistance are multidrug efflux pumps, which 
are able to recognize a large number of compounds other than their natural 
substrates. Aminocoumarin antibiotics are recognized by several of them (Nikaido, 
1998), e.g. by the multidrug transporter ABC (Nagakubo et al., 2002). 
 
2.5. Clinical applications 
 
The aminocoumarin antibiotics are active against Gram-positive bacteria, including 
methicillin-resistant S. aureus (MRSA). However, due to their toxicity in eukaryotes, 
their poor solubility in water, preventing the development of parenteral dosage forms, 
and their low activity against Gram-negative bacteria, their clinical use remains 
limited (Maxwell, 1993). In contrast to clorobiocin and coumermycin A1, novobiocin 
(Albamycin®, Pharmacia & Upjohn) was licensed for clinical use in the USA. It was 
initially approved by FDA in 1964 for the treatment of “serious infections due to 
susceptible strains of S. aureus when other less toxic antibiotics e.g. penicillins, 
vancomycin and tetracyclines, cannot be used” (FDA, 2011) and its efficacy was 
shown in several preclinical and clinical trials (Arathoon et al., 1990; Raad et al., 
1998; Walsh et al., 1993). However, in 2009 FDA withdraw its approval for reasons of 
safety or effectiveness after Pharmacia & Upjohn (now Pfizer, Inc.) already stopped 
production in 1999. Among the safety concerns reported were adverse reactions (e.g. 
skin reactions, hepatic failure and blood dyscrasias), the development of novobiocin-
resistance during treatment, and the potential for drug interactions (FDA, 2011). 
 
8 I. INTRODUCTION   
 
Further studies showed that the aminocoumarin antibiotics act synergistically with 
certain antitumor drugs, e.g. with the topoisomerase II inhibitors etoposide and 
teniposide. It was demonstrated that novobiocin enhances the cytotoxicity of 
etoposide and increases the formation of drug-stabilized topoisomerase II-DNA 
complexes in several drug-sensitive and -resistant tumor cell lines. Although 
novobiocin was shown to inhibit topoisomerase II at higher concentrations, the 
mechanism involved is more likely the inhibition of etoposide efflux resulting in a 
higher intracellular concentration of this drug (Rappa et al., 1993; Rappa et al., 
2000a; Rappa et al., 2000b).  
 
The eukaryotic heat shock protein 90 (Hsp90) plays a key role in the stability and 
function of multiple cell-signalling molecules including several oncogenic tyrosine and 
serine-threonine kinases. It is therefore considered as a novel target for anticancer 
drugs (Marcu et al., 2000). The aminocoumarins, novobicin, clorobiocin and 
coumermycin A1 respectively, were shown to bind to the C-terminal part of Hsp90 
and thereby interfere with its chaperon function. Subsequently, tumor cells were 
depleted of a series of Hsp90-dependent signalling proteins, e.g. Raf-1 (Allan et al., 
2006; Marcu et al., 2000). However, the affinity of novobiocin for Hsp90 is poor (IC50 
700 µM) and therefore, several analogs of novobiocin and coumermycin A1 with 
higher affinity and selectivity for Hsp90 were generated in the last years (Burlison & 
Blagg, 2006; Burlison et al., 2006). 
 
Recently, coumermycin A1 was also shown to possess potent antiretroviral activity. It 
impairs viral gene expression in acutely infected cells probably by preventing Hsp90 
dimerization and is additionally able to inhibit HIV-1 integration by targeting the 
capsid protein. Novobiocin also shows some antiretroviral activity but lower than that 
of coumermycin A1 (Vozzolo et al., 2010). 
 
 
3. Liponucleoside antibiotics 
 
The caprazamycins (CPZ) and liposidomycins (LPM) are liponucleoside antibiotics of 
unusual complexity that inhibit the bacterial peptidoglycan synthesis. The 
liposidomycins were isolated in 1985 from a culture broth of Streptomyces 
griseosporeus and, based on the HPLC profile, consisted of at least 12 compounds 
(Isono et al., 1985; Ubukata et al., 1988). The caprazamycins are produced by 
Streptomyces sp. MK730-62F2 and were identified in 2003 in a screening for new 
anti-mycobacterial antibiotics (Igarashi et al., 2003). Recently, the gene clusters of 
caprazamycins (Kaysser et al., 2009) and liposidomycins (Kaysser et al., 2010a), 
respectively, were identified by our group. 
 
3.1. Chemical structure 
 
The core structure of both liposidomycins and caprazamycins is the (+)-caprazol 
(Figure I.5), consisting of a 5‟-substituted uridine, a 5-amino-5-deoxyribose and a N-
methylated perhydro-1,4-diazepine moiety. Fatty acids of different chain lengths and 
conformations are attached to the 3‟‟‟-OH group of the diazepanone ring and 
distinguish the different liposidomycins and caprazamycins, respectively. Attached to 
the β-hydroxy group of the fatty acid side chain is a rare 3-methylglutaryl (3-MG) 
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moiety which, in case of the caprazamycins, is linked to a permethylated L-rhamnose. 
A sulfate group at the 2‟‟-position of the aminoribose is the only other difference 
between the liposidomycins and the caprazamycins (Figure I.5). The muraymycins 
(McDonald et al., 2002) and FR-900493 (Ochi et al., 1989) also exhibit the 5‟-β-O-
aminoribosyl-5‟-C-glycyluridine core moiety contained in the caprazamycins and 
liposidomycins. 
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Figure I.5 
Chemical structures of caprazamycins, liposidomycins and (+)-caprazol. The structural 
differences between caprazamycins and liposidomycins are shaded in grey. 
 
 
3.2. Mechanism of action and bioactivity 
 
The biosynthesis of peptidoglycan, a major component of the bacterial cell wall, is 
essential for all bacteria and therefore represents one of the most important targets 
for antibiotics. It consists of alternating N-acetylglucosamine (GlcNAc) and N-
acetylmuramic acid (MurNAc) units, that are β-1,4-glycosidically linked. Attached to 
the D-lactoyl group of MurNAc is a pentapeptide side chain, which consists of L-
alanine, γ-D-glutamate, L-lysine or meso-diaminopimelic acid (DAP), and two D-
alanines. Cross-linking of the peptidoglycan generally occurs between the carboxyl 
group of the D-alanine at position 4 and the amino group of lysine/DAP at position 3 
(Barreteau et al., 2008; Kimura & Bugg, 2003). The assembly of peptidoglycan 
involves several steps and takes place in different compartments of the cell, i.e. in the 
cytoplasm and at the inner and outer side of the cytoplasmatic membrane. The first 
step is the synthesis of the nucleotide precursors, UDP-GlcNAc and UDP-MurNAc-
pentapeptide, which takes place in the cytoplasm. Subsequently, the phospho-
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MurNAc-pentapeptide moiety is transferred from UDP to the membrane acceptor 
undecaprenyl phosphate (C55-P), generating lipid I. This reaction is catalysed by the 
translocase I MraY. A second transferase, MurG, then catalyzes the transfer of 
GlcNAc to lipid I yielding lipid II. After its passage through the membrane, by a yet 
unknown mechanism, lipid II is used as the substrate for the polymerization reaction 
(Figure I.6) (Al-Dabbagh et al., 2008; Bouhss et al., 2008). 
 
 
Liposidomycins
Fosfomycin
Enduracidin
VancomycinPenicillin
Moenomycin
 
 
Figure I.6 
Biosynthesis of the bacterial cell wall and some antibiotics inhibiting it. Modified from Al-
Dabbagh et al. (2008). 
 
 
The liposidomycins are potent inhibitors of the peptidoglycan biosynthesis (ID50 0.03 
µg/mL) and were shown to target translocase I with high specificity (Isono et al., 
1985; Kimura et al., 1989). Eukaryotic glucoconjugate formation, in comparison, was 
only inhibited at high dosages (Muroi et al., 1997) and no toxic effects of the 
liposidomycins were observed in mice after intravenous administration of 180 mg/kg 
(Isono et al., 1985). Although their in vitro activity is high, the antibacterial activity of 
the liposidomycins is limited, with Mycobacterium phlei (MIC 0.16 µg/mL) being the 
most sensitive bacterium (Isono et al., 1985; Kimura et al., 1989). Kimura and co-
workers (Kimura et al., 1998a; 1998b; 1998c) suggested that, due to the presence of 
the hydrophilic sulfate group, the permeability of the liposidomycins is limited. 
Accordingly, its removal resulted in an improved antimicrobial activity, while the in 
vitro activity remained nearly the same (Kimura et al., 1998a; 1998b; 1998c). Further 
studies indicate that the 3‟‟-OH group (Dini et al., 2001b), the amino group of the 
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aminoribose and an intact uracil moiety (Dini et al., 2001a) are essential for the 
inhibition of Escherichia coli translocase I. The fatty acid side chain was suggested to 
play a role in the penetration of the bacterial cell (Hirano et al., 2008). 
 
The caprazamycins resemble the liposidomycins and were therefore also assigned to 
the translocase I inhibitor family (Kimura & Bugg, 2003). They show excellent activity 
in vitro against Gram-positive bacteria, especially against Mycobacteria, e.g. M. 
tuberculosis (MIC 0.78 – 1.56 µg/mL), M. avium (MIC <0.025 – 0.1 µg/mL) and M. 
intracellulare (MIC 0.78 – 1.56 µg/mL) (Takeuchi et al., 2001). In a pulmonary mouse 
model with M. tuberculosis H37Rv, caprazamycin B showed a therapeutic effect at 
1.5 mg/kg/day but no significant toxicity was observed (Igarashi et al., 2002).  
 
The peptidyl nucleoside antibiotics, e.g. the mureidomycins, pacidamycins and 
napsamycins, and the tunicamycin-type liponucleoside antibiotics, e.g. the 
tunicamycins, streptoviridins and corynetoxins, also belong to the translocase I 
inhibitor family (Kimura & Bugg, 2003). 
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4. Aims of this study 
 
 
The main objectives of this study were: 
 
 
1) To establish 24-square deepwell plates with sandwich covers in our 
laboratory as a new cultivation system for Streptomyces, which 
shows a reduced variability of the production rates in comparison to 
Erlenmeyer flasks. 
 
Investigations on antibiotic formation in streptomycetes are often hampered 
by the notorious variability of production rates, observed between different 
cultivation batches, in Erlenmeyer flasks, and therefore a cultivation 
method that shows less variability in secondary metabolite production could 
probably reduce the workload and cost of research in antibiotic 
biosynthesis significantly. In order to test whether the variability of antibiotic 
production in Streptomyces can be reduced by cultivation in 24-square 
deepwell plates (Duetz, 2007), novobiocin production in the heterologous 
producer strain S. coelicolor M512(novBG01) was investigated in this new 
cultivation system. To obtain similar production rates as in the Erlenmeyer 
flasks as well as a low variability, it was necessary to optimize the 
inoculation method, to prepare frozen inoculum either from the early 
stationary phase or from a defined section of the growth phase and to test 
the influence of aeration and of a siloxylated ethylene oxide/propylene 
oxide copolymer as artificial oxygen carrier as well as the overexpression 
of the pathway-specific positive regulator NovG. 
 
For the production of coumermycin A1 and its derivatives in the 24-square 
deepwell plates, it was necessary to optimize the inoculation ration and to 
test different production media, since the originally used SK medium was 
not suitable, due to the lard oil contained therein. 
 
 
2) To show that the genes couR1-4, but not couN1-7, are involved in the 
biosynthesis of the central 3-methylpyrrole-2,4-dicarboxylic acid 
moiety of coumermycin A1. 
 
Coumermycin A1 contains two types of pyrrole moieties, i.e. two terminal 5-
methylpyrrole-2-carboxyl moieties and the central 3-methylpyrrole-2,4-
dicarboxylic acid moiety. While the biosynthesis of the terminal pyrrole 
moieties from L-proline by action of CouN1-7 is well investigated, the 
biosynthetic pathway to the central pyrrole moiety is still unknown. Deletion 
of the genes couN1-7 together with couM, coding for the glycosyl 
transferase responsible for the attachment of the deoxysugar moiety to the 
aminocoumarin ring, was attempted to show whether these genes are also 
involved in the biosynthesis of the central pyrrole moiety. 
 
The genes couR1-4 within the coumermycin gene cluster have no 
orthologs in the gene clusters of novobiocin and clorobiocin and are not yet 
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functionally assigned. In order to prove that these genes are involved in the 
biosynthesis of coumermycin A1, couR1-couR4 were deleted separately on 
cosmid couMW16 by RED/ET mediated recombination. This work was 
carried out by Anna Knuplesch and is described in her diploma thesis. We 
now attempted heterologous expression of the resulting cosmids couAK06-
couAK10 in S. coelicolor M1146 followed by complementation and feeding 
of 3-methylpyrrole-2,4-dicarboxylic acid, to prove that all five genes are not 
only involved in the biosynthesis of coumermycin A1 but specifically in the 
biosynthesis of the central pyrrole moiety.  
 
 
3) To prove that L-threonine is one of the precursors of the central 
pyrrole moiety of coumermycin A1 and that the intact L-threonine 
molecule is incorporated. 
 
CouR3 shows similarity to the L-threonine kinase PduX from Salmonella 
enterica and therefore the first step in the biosynthesis of the central 
pyrrole moiety may be the phosphorylation of L-threonine catalysed by 
CouR3. Consequently, we attempted to show that CouR3 acts as a L-
threonine kinase by feeding of O-phospho-L-threonine to a couR3-defective 
mutant. 
 
In order to prove that L-threonine is one of precursor of the central pyrrole 
moiety a feeding experiment with [U-13C,15N]L-threonine followed by LC-MS 
and 13C-NMR analysis was attempted. The identification of the second 
precursor necessitates an additional feeding experiment and therefore 
feeding of [U-13C]fumaric acid was tried. The NMR analysis was conducted 
in cooperation with Nadja Burkard and Prof. Stephanie Grond (Organic 
chemistry department, University of Tübingen, Germany). 
 
 
4) To establish a LC/ESI-MS/MS method for the identification of 
caprazamycins and liposidomycins in culture extracts of the 
respective producer strains and to adapt a chromatographic method 
using a boronic acid stationary phase for the partial purification of 
caprazamycins and liposidomycins 
 
The identification of caprazamycins, liposidomycins, and derivatives 
thereof, e.g. resulting from gene inactivations, requires a rapid and precise 
analytical method that also supplies sufficient structural information. High-
performance liquid chromatography (HPLC) coupled to a triple-stage 
quadrupole mass spectrometer (MS) is capable of both, separating 
complex mixtures of secondary metabolites and providing reliable 
information on the analyte‟s mass and structure. In order to get as much 
structural information as possible LC/ESI-MS/MS analysis was attempted 
in positive as well as in negative ionization mode followed by the 
assignment of characteristic fragment ions. 
 
Affi-Gel® boronate is a boronic acid-containing gel that specifically binds 
cis-diol structures, like the ribose of nucleosides, at alkaline pH values by 
formation of a cyclic boronate ester. At acidic pH values the ester bond is 
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cleaved resulting in the elution of the cis-diol-containing compounds. Since 
the liponucleoside antibiotics also contain a nucleosidic structure, 
purification was attempted using a method originally developed for the 
purification of modified nucleosides from cell cultures. 
 
 
5) To identify new caprazamycins in the culture extracts of 
Streptomyces sp. MK730-62F2. 
 
Previously, 27 liposidomycin derivatives containing 13 different fatty acid 
side chains have been isolated from Streptomyces sp. SN-1061. In 
contrast, only seven caprazamycins were reported from Streptomyces sp. 
MK730–62F2. Since both gene clusters are highly conserved and do not 
contain possible genes for fatty acid biosynthesis, the fatty acid moiety of 
the liponucleoside antibiotics is most likely provided by the primary 
metabolism of the host strain. We therefore attempted to identify new 
caprazamycins in the culture extracts of Streptomyces sp. MK730-62F2 by 
precursor ion scans in positive and negative mode, respectively. This 
method allows the identification of new derivatives from a known structural 
class of compounds by scanning for product ions that are characteristic for 
the whole class. 
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II. MATERIALS AND METHODS 
 
1. Chemicals, materials for chromatography and enzymes 
1.1. Chemicals 
 
Chemicals used in this thesis were obtained mainly from Fluka (Ulm), Merck 
(Darmstadt), Roth (Karlsruhe) and Sigma-Aldrich (Taufkirchen), media components 
mainly from Becton-Dickinson (Heidelberg). Special chemicals and media 
components are listed in Table II.1. 
 
 
Table II.1 Special chemicals and media components 
 
Supplier Chemical / Media component 
Becton-Dickinson, Heidelberg, 
Germany 
Malt extract 
Proteose Pepton No. 3 
Soytone 
Soluble starch 
Tryptone 
Tryptone Soya Broth (TSB) 
Yeast extract 
Biozyme Scientific GmbH, Oldendorf, 
Germany 
Agarose 
Calbiochem-Novabiochem, Bad 
Soden, Germany 
Thiostreptone 
CGeneTech, Indianapolis, USA 3-methylpyrrole-2,4-dicarboxylic acid diethyl ester 
Dow Corning, Auburn, USA siloxylated ethylene oxide/propylene oxide 
copolymer Q2-5247 
Eurisotop, Saarbrücken, Germany [U-13C] fumaric acid 
Fluka, Ulm, Germany Novobiocin 
Fisher Scientific, Schwerte, Germany Acetonitrile LCMS grade 
Methanol LCMS grade 
Genaxxon Biosciences, Biberach, 
Germany 
Apramycin 
Chloramphenicol 
Kanamycin 
Merck, Darmstadt, Germany Ethanol 
D-Maltose 
Methanol 
Roth, Karlsruhe, Germany 
 
Agar 
Bromphenol blue 
Carbenicillin 
EDTA 
Formic acid 
Glacial acetic acid 
Glucose 
Glycerol 
Mannitol 
Phenol/Chloroform/Isoamyl alcohol (25:24:1) 
Phosphorus pentoxide 
L-Proline 
SDS 
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Supplier Chemical / Media component 
Sigma-Aldrich, Taufkirchen, Germany Acetonitrile HPLC grade 
Brewers yeast 
Coumermycin A1 
Dimethyl sulfoxide (DMSO) 
Lard oil 
Methanol HPLC grade 
Nalidixic acid 
[U-13C,15N]L-threonine 
Tris base 
SOBO Naturkost, Köln, Germany Soy flour 
Südzucker, Mannheim, Germany Sucrose 
VWR, Darmstadt, Germany Acetonitrile HPLC grade 
Methanol HPLC grade 
 
1.2. Materials for chromatography 
 
The liquid chromatography media were obtained as commercial columns or dry 
material. Columns and media were stored according to the manufacturers‟ 
instructions. 
 
Table II.2 Materials for chromatography 
 
Supplier Medium 
Bio-Rad, Munich, Germany Affi-Gel® boronate (dry material) 
C+S Chromatographie Service, 
Düren, Germany 
Multoprep® RP18 – 25/40 µm (dry material) 
Dr. Maisch GmbH, Ammerbuch, 
Germany 
Reprosphere® C18-DE (commercial column, 5 µm, 
150 x 3 mm) 
Reprosphere® C18-DE (commercial column, 5 µm, 
150 x 4.6 mm) 
Reprosil-Pur® Basic C18 (commercial column, 5 
µm, 250 x 2 mm) 
Ziemer Chromatographie, 
Langerwehe, Germany 
Multosphere® 120 RP18 (commercial column, 5 
µm, 250 x 8 mm) 
 
1.3. Enzymes and kits 
 
Enzymes and kits used in this study are listed in Table II.3 and were stored according 
to the manufacturers‟ instructions. 
 
Table II.3 Enzymes and kits 
 
Supplier Enzymes and kits 
Fermentas GeneRuler® 1kb DNA ladder 
Fluka, Ulm, Germany Lysozyme 85400 U/mg 
Genaxxon Biosciences, Biberach, Germany 10 mM dNTP-mix (2.5 mM each) 
New England Biolabs, Frankfurt, Germany Restriction endonucleases 
T4 DNA Ligase 
Quiagen, Hilden, Germany RNase A 100 mg/mL 
QIAquick PCR Purification kit 
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2. Media, buffers and solutions 
2.1. Media for bacterial cultivation 
 
Unless stated otherwise, the media were prepared with distilled water and autoclaved 
for 20 min at 121°C. To obtain solid media, 2% (w/v) agar was added before 
autoclaving. All recipes are given for 1 L of final volume. If necessary, supplementary 
components like antibiotics or other heat labile substances were added to the media 
as sterile solutions (filtered through 0.22 µm pore sized filters) at the time of use. The 
media were stored at 4°C or at room temperature. 
 
2.1.1. Cultivation of E. coli 
 
LB (Luria-Bertani) medium (Sambrook & Russell, 2001) 
 
NaCl 10.0 g 
Tryptone 10.0 g 
Yeast extract 5.0 g 
 
The components were dissolved in 1 L water, adjusted to pH 7.0 and sterilized by 
autoclaving. 
 
2.1.2. Cultivation of Streptomyces 
 
YMG (Yeast-Malt-Glucose) medium 
 
Yeast extract 4.0 g 
Malt extract 10.0 g 
Glucose 4.0 g 
 
The components were dissolved in 800 mL water, filled up to 1 L after the pH was 
adjusted to 7.3 and sterilized by autoclaving. 
 
 
TSB (Tryptone Soya Broth) medium (Kieser et al., 2000) 
 
Tryptone Soya Broth 30.0 g 
 
The component was dissolved in 1 L water and sterilized by autoclaving. 
 
 
2 x YT medium (Kieser et al., 2000) 
 
Tryptone 16.0 g 
Yeast extract 10.0 g 
NaCl 5.0 g 
 
The components were dissolved in 1 L water and sterilized by autoclaving 
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MS (Mannitol Soya flour) agar (Kieser et al., 2000) 
 
Mannitol 20.0 g 
Soya flour 20.0 g 
Agar 20.0 g 
 
The mannitol was dissolved in 1 L tap water and 100 mL were poured into each flask 
containing 2 g agar and 2 g soya flour. The medium was sterilized twice by 
autoclaving (115°C, 15 min) with gentle shaking of the medium between the two 
runs. 
 
2.1.3. Media for secondary metabolite production 
2.1.3.1. Media for novobiocin production 
 
CDM (Chemical Defined Medium) (Kominek, 1972) 
 
tri-sodium citrate . 2H2O 6.0 g 
L-proline 6.0 g 
K2HPO4 
. 3H2O 2.0 g 
(NH4)2SO4 1.5 g 
NaCl 5.0 g 
 
The components were dissolved in 800 mL water and adjusted to pH 7.2 
 
MgSO4 
. 7H2O 2.05 g 
CaCl2 
. 2H2O 0.4 g 
FeSO4 
. 7H2O 0.2 g 
ZnSO4 
. 7H2O 0.1 g 
  
Glucose 30% (w/v) 100 mL 
 
The components, except the glucose solution, were dissolved in the first solution and 
water was added to 900 mL. The pH was again adjusted to 7.2 and medium and 
glucose solution were sterilized by autoclaving and mixed prior to use. 
 
2.1.3.2. Media for coumermycin A1 production 
 
SK medium (Scannell & Kong, 1969) 
 
Soluble starch 20.0 g 
Pharma medium 20.0 g 
Lard oil 20.0 g 
Yeast extract 4.0 g 
K2HPO4 
. 3 H2O 2.5 g 
CaCl2 
. 2 H2O 0.5 g 
CoCl2 
. 6 H2O 200 µg 
 
The components were dissolved in 1 L water and sterilized by autoclaving. 
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Coumermycin production medium 1 (Weinstein et al., 1978) 
 
Soluble starch 60.0 g 
Brewers yeast 30.0 g 
CaCO3 10.0 g 
 
The components were dissolved in 1 L water and sterilized by autoclaving. 
 
 
Coumermycin production medium 2 (Kawaguchi et al., 1965) 
 
Glucose 30.0 g 
Pharma medium 35.0 g 
Glycerol 86% 2.3 g 
Yeast extract 2.0 g 
K2HPO4 
. 3 H2O 5.0 g 
KCl 2.0 g 
CaCO3 8.0 g 
CoCl2 
. 6 H2O 200 µg 
 
The components were dissolved in 1 L water and sterilized by autoclaving. 
 
2.1.3.3. Media for caprazamycin and liposidomycin production 
 
P medium (Kaysser et al., 2009) 
 
Soytone 10.0 g 
Soluble starch 10.0 g 
D-maltose 20.0 g 
Trace elements solution 5.0 mL 
 
The components were dissolved in water, filled up to 1 L after adjustment to pH 6.7 
and sterilized by autoclaving. 
  
Trace elements solution 
 
ZnCl2 40 mg 
FeCl3 
. 6H2O 200 mg 
CuCl2 
. 2H2O 10 mg 
MnCl2 
. 4H2O 10 mg 
Na2B4O7 
. 10H2O 10 mg 
(NH4)6Mo7O24 
. 4H2O 10 mg 
 
The components were dissolved in 1 L water and sterilized by autoclaving 
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2.2. Antibiotic solutions 
 
The antibiotics were dissolved in an appropriate solvent and the stock solutions were 
kept at -20°C. Aqueous solutions were sterilized by filtration through 0.22 µm pore 
size filters, solutions in ethanol and DMSO are autosterile. The required antibiotics 
were added to the media (RT to 60°C) in the appropriate concentration. 
 
 
Table II.4 Antibiotic solutions 
 
Antibiotic 
Concentration in 
Solvent Stock solution 
(mg/mL) 
Medium 
(µg/mL) 
Apramycin 50 15-50a H2O 
Chloramphenicol 15-50 25-50 ethanol 
Nalidixic acid 25 25 0.3 M NaOH 
Kanamycin 50 15-50a H2O 
Thiostrepton 50 15-50a DMSO 
a15 µg/mL in liquid and 50 µg/mL on solid media for selection of Streptomyces strains; 
otherwise 50 µg/mL 
 
 
2.3. Buffers and solutions 
 
Unless stated otherwise, buffers and solutions were prepared with distilled water, 
autoclaved (121°C, 20 min) and stored at room temperature. 
 
2.3.1. Buffers and solutions for DNA isolation 
 
Buffers and solutions for the isolation of plasmids and cosmids from E. coli are listed 
in Table II.5, the buffers and solutions required for the isolation of genomic DNA from 
Streptomyces in Table II.6. 
 
 
Table II.5 Buffers and solutions for plasmid and cosmid isolation from E.coli 
 
Buffer Components Final concentration Preparation 
MP 1 Glucose 
Tris-HCl 
EDTA 
RNase A 
50 mM 
25 mM 
10 mM 
100 µg/mL 
Adjust to pH 8.0. Add 
RNase A just before use 
MP 2 NaOH 
SDS 
0.2 N 
1% (w/v) 
 
MP 3 K(CH3COO) 3 M Adjust to pH 4.8. Store at 
4°C 
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Table II.6 Buffers for isolation of genomic DNA from Streptomyces 
 
Buffer Components Final concentration Preparation 
TSE buffer Sucrose 
Tris-HCl 
EDTA 
10.3% 
25 mM 
25 mM 
Adjust to pH 8.0 
TE buffer Tris-HCl 
EDTA 
10 mM 
1 mM 
Adjust to pH 7.5 
Lysozyme solution TSE buffer 
Lysozyme 
RNase A 
- 
3 mg/mL 
100 µg/mL 
Add RNase A and 
lysozyme just before 
use 
SDS solution SDS 2% (w/v)  
NaOAc solution Na(CH3COO) 3 M Adjust to pH 4.8 
Tris buffer Tris-HCl 10 mM Adjust to pH 8.0 
 
 
2.3.2. Buffers for DNA gel electrophoresis 
 
Table II.7 Buffers for DNA gel electrophoresis 
 
Buffer Components Final Concentration Preparation 
50x TAE Tris base 
EDTA 
Glacial acetic acid 
2 M 
0.05 M 
57.1 mL/L 
Adjust to pH 8.0 with 
glacial acetic acid 
Loading buffer Glycerol 
Bromphenol blue 
30% (w/v) 
0.25% (w/v) 
Store at 4°C 
Ethidium bromide 
solution 
Ethidium bromide 1 mg/L  
 
2.3.3. Buffers and solutions for affinity chromatography with Affi-Gel® 
boronate 
 
Table II.8 Buffers and solutions for affinity chromatography with Affi-Gel® boronate 
 
Buffer Components Final Concentration Preparation 
NH4OAc 
buffer 
NH4(CH3COO) 0.25 M Adjust to pH 8.8 with 
NH3 25% 
Formic acid 
solution 
MeOH/H2O 1:1 (v/v) 
Formic acid 
- 
0.2 M 
 
NaCl solution NaCl 0.1 M  
 
 
 
 
 
 
 
 
 
22 II. MATERIALS AND METHODS   
 
3. Plasmids, cosmids, bacterial strains and primers 
3.1. Vectors, plasmids and cosmids 
 
All vectors, plasmids and cosmids used in this study are listed with their respective 
sources in Table II.9. 
 
Table II.9 Vectors, plasmids and cosmids 
 
Name Description Source or reference 
Vectors 
 
  
pUWL-Apra-
oriT 
E. coli - Strepromyces shuttle vector, oriT, ermE* 
promoter; ApraR, CarbR 
Andrease Günther, 
Albert Ludwigs 
Universität Freiburg 
pWHM3 E. coli - Strepromyces shuttle vector, lacZα; 
AmpR, ThioR 
(Vara et al., 1989) 
Plasmids 
 
  
pUZ8002 tra, RP4; KanR (Paget et al., 1999) 
pUB307 „Driver“-Plasmid for triparental conjugation; tra, 
oriT ; KanR, CmlR 
(Flett et al., 1997) 
pIJ773 aac(3)IV (ApraR), oriT, FRT (Gust et al., 2003) 
pAE12 1.35 kb PstI-SphI fragment of pAE11 cloned 
into the same sites of pWHM3, containing novG; 
AmpR ThioR 
(Eustáquio, 2004) 
pAK06 1.4 kb HindIII/SpeI fragment of pAK01 cloned 
into the same sites of pUWL-Apra-oriT, 
containing couR1; ApraR 
(Knuplesch, 2008) 
pAK10 1.2 kb HindIII/SpeI fragment of pAK05 cloned 
into the same sites of pUWL-Apra-oriT, 
containing couR4; ApraR 
(Knuplesch, 2008) 
Cosmids 
 
  
novBG01 From cosmid 10-9C, bla gene replaced by 
cassette from pIJ787 (oriT, tet, attP, int ΦC31); 
KanR. 
Bertolt Gust 
(Eustáquio et al., 
2004) 
couMW16 Integrative cosmid with complete coumermycin 
A1 gene cluster; attP, int, tet, oriT; Kan
R, CarbR 
(Wolpert et al., 2008) 
couMW22 From couMW16, couM-couN7 (position 10985-
19284 in AF235050) replaced by the apramycin 
resistance cassette from pIJ773; ApraR, KanR 
Final report of Manuel 
Wolpert 
couSS01 From couMW22, apramycin resistance cassette 
removed by XbaI digestion and religation; KanR 
This thesis 
couAK06 From couMW16, couR1 (position 21980-22753 in 
AF235050) replaced by the apramycin resistance 
cassette from pIJ773; resistance cassette 
removed by XbaI/SpeI digestion and religation; 
KanR 
(Knuplesch, 2008) 
couAK07 From couMW16, couR2a (position 23206-23472 
in AF235050) replaced by the apramycin 
resistance cassette from pIJ773; resistance 
cassette removed by XbaI/SpeI digestion and 
religation; KanR 
(Knuplesch, 2008) 
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Name Description Source or reference 
couAK08 From couMW16, couR2b (position 23752-24056 
in AF235050) replaced by the apramycin 
resistance cassette from PIJ773; resistance 
cassette removed by XbaI/SpeI digestion and 
religation 
(Knuplesch, 2008) 
couAK09 From couMW16, couR3 (position 24248-25150 in 
AF235050) replaced by the apramycin resistance 
cassette from pIJ773; resistance cassette 
removed by XbaI/SpeI digestion and religation 
(Knuplesch, 2008) 
couAK10 From couMW16, couR4 (position 25211-26374 in 
AF235050) replaced by the apramycin resistance 
cassette from pIJ773 ; resistance cassette 
removed by XbaI/SpeI digestion and religation 
(Knuplesch, 2008) 
 
3.2. Bacterial strains 
 
The bacterial strains used in this study are listed with their respective sources in 
Table II.10. 
 
Table II.10 E. coli and Streptomyces strains used in this study 
 
Strain Description Source or 
reference 
E.coli 
 
  
E. coli XL1 Blue 
MRF- 
General cloning host; recA1, endA1, gyrA96, 
thi-1, hsdR17, supE44, relA1, lac [F´, proAB, 
laclq, ZΔM15, Tn10]; TetR 
Stratagene 
E. coli ET12567 
 
DNA methylase negative strain (dam- dcm- 
hsdM); TetR, CmlR 
(MacNeil et al., 
1992) 
Streptomyces 
 
  
S. coelicolor M512 S. coelicolor M145 derivative; ΔredD, ΔactII-
ORF4, SCP1-, SCP2- 
(Floriano & Bibb, 
1996) 
S. coelicolor M1146 S. coelicolor M145 derivative; SCP1-, SCP2-, 
Δact, Δred, Δcda, Δcpk 
(Gomez-Escribano 
& Bibb, 2011) 
S. coelicolor M512 
(novBG01) 
S. coelicolor M512 containing cosmid 
novBG01 
(Eustáquio et al., 
2004) 
S. coelicolor M512 
(novBG01)/pWHM3 
S. coelicolor M512(novBG01) containing the 
empty vector pWHM3; KanR, ThioR 
(Siebenberg et al., 
2010) 
S. coelicolor M512 
(novBG01)/pAE12 
S. coelicolor M512(novBG01) containing the 
plasmid pAE12 (novG); KanR, ThioR 
(Siebenberg et al., 
2010) 
S. coelicolor M1146  
(couMW16) 
S. coelicolor M1146 containing cosmid  
couMW16; KanR 
(Flinspach et al., 
2010) 
S. coelicolor M1146 
(couSS01) 
S. coelicolor M1146 containing cosmid 
couSS01 (ΔcouM-couN7); KanR 
This thesis 
S. coelicolor M1146 
(couAK06) 
S. coelicolor M1146 containing cosmid 
couAK06 (ΔcouR1); KanR 
This thesis 
S. coelicolor M1146 
(couAK06)/pAK06 
S. coelicolor M1146(couAK06) containing 
plasmid pAK06 (couR1); KanR, ApraR 
This thesis 
S. coelicolor M1146 
(couAK07) 
S. coelicolor M1146 containing cosmid 
couAK07 (ΔcouR2a); KanR 
This thesis 
24 II. MATERIALS AND METHODS   
 
Strain Description Source or 
reference 
S. coelicolor M1146 
(couAK09) 
S. coelicolor M1146 containing cosmid 
couAK09 (ΔcouR3); KanR 
This thesis 
S. coelicolor M1146 
(couAK10) 
S. coelicolor M1146 containing cosmid 
couAK10 (ΔcouR4); KanR 
This thesis 
S. coelicolor M1146 
(couAK10)/pAK10 
S. coelicolor M1146(couAK10) containing 
plasmid pAK10 (couR4); KanR, ApraR 
This thesis 
Streptomyces sp. 
MK730-62F2 
caprazamycin producer; wildtype strain acc. no. 
FERMBP7218 
(National 
Institute of 
Bioscience and 
Human 
Technology, 
Tsukuba, Japan) 
Streptomyces sp. 
SN-1061M 
liposidomycin producer; obtained from UV-
mutagenesis of the wildtype strain. 
acc. no. 
FERMBP5800 
(National 
Institute of 
Bioscience and 
Human 
Technology, 
Tsukuba, Japan) 
 
3.3. PCR primers 
 
All primers listed in Table II.11 were purchased from Eurofins MWG (Ebersberg, 
Germany). 
 
Table II.11 Primers 
 
Name Sequence (5‟  3‟)a 
Primers for the deletion of couM-couN7 
 
couM_fwd CCG GAC GTG CTG GTG GAC AGG TGA GGT GAG 
TCA TTC GAT GTC TAG ATG TAG GCT GGA GCT 
GCT TC 
couN7_rev CGG ATT CCG TGG GCG TGA TGC CGG TCG GTT 
CCG GAT CTT AAC TAG TAT TCC GGG GAT CCG 
TCG ACC 
Primers for testing of couSS01 (ΔcouM-couN7) 
 
couSS01_f GTG GAT GCG TGC GTG TAC G 
couSS01_r CGA TGC GAT GGT GTG GAA GG 
Primers for testing of couAK06 – couAK10 (ΔcouR1-ΔcouR4) 
 
kont_couR1_f CGG GTA TGT GGA CCA CCC GG 
kont_couR1_r CGA CCG GTC GTC AGG ATC CG 
kont_couR2a_f CTG TTG CGC GGC GCC GAC TT 
kont_couR2a_r ACT CGG CGG CCA GCA ACA GC 
kont_couR2b_f ACG GTC ATC AGC GTC CGG GG 
kont_couR2b_r CAT CGC ACA TCC GGC GGA CC 
kont_couR3_f GCC GCC GAG TTC ACC GGG TT 
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Name Sequence (5‟  3‟)a 
Primers for testing of couAK06 – couAK10 (ΔcouR1-ΔcouR4) (continuation) 
 
kont_couR3_r CGA TCC TGC TAC CGG CTG CG 
kont_couR4_f TGG ACC GGG GAT TCC GGC TG 
kont_couR4_r AGC GGG CTG GTG ATC GGA CC 
Primers for amplification of couE, couO and gyrB (presence of coumermycin gene 
cluster) 
 
couE_fwd ACT TCC GTC GGA AGC CGT CG 
couE_rev ACC GTG AGG ACC TTC CGC C 
couO_fwd GAG ACC TCC CTA CCG CGA AC 
couO_rev CCG ATG ACT CCT TCG ACG TC 
gyrB_fwd GAC TGG TTC GAC CGC AAC CC 
gyrB_rev CCG TCG AGC ACC ATC AGG TG 
a the priming sequence for pIJ773 is shown in bold, SpeI (ACTAGT) and XbaI (TCTAGA) 
restriction sites are underlined 
 
 
4. Culture Conditions 
4.1. Cultivation of E. coli 
 
E. coli strains were cultivated in liquid or on solid LB medium, supplemented with the 
appropriate antibiotic(s), at 37°C overnight (16-18 h). Standard methods for 
cultivation were performed as described by Sambrook & Russell (2001). 
 
4.2. Cultivation of Streptomyces 
4.2.1. General cultivation conditions 
 
Streptomyces strains were cultivated either on MS agar or in liquid YMG or TSB 
medium. Cultivations in liquid media were carried out in 300 mL baffled Erlenmeyer 
flasks, containing a stainless steel spring and 50 mL of the respective medium, at 
180-220 rpm and 30°C for 2 days. If required, an appropriate amount of antibiotic(s) 
was added to the medium. 
 
4.2.2. Production of secondary metabolites 
 
Cultivations were carried out either in 300 mL baffled Erlenmeyer flasks containing a 
stainless steel spring or in 24-square deepwell plates (Duetz et al., 2000), without the 
addition of antibiotic(s). 
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4.2.2.1. Production of novobiocin 
 
Cultivation in Erlenmeyer flasks 
 
For novobiocin production, 1 mL of a YMG preculture of S. coelicolor 
M512(novBG01) was used to inoculate a 300 mL baffled Erlenmeyer flask containing 
50 mL of CDM medium. The cultivation was carried out at 30°C and 200 rpm for 7 
days. 
 
Cultivation in 24-square deepwell plates 
 
For cultivation in 24-square deepwell plates, 40 mL of CDM medium were mixed 
either with 0.5 mL of YMG preculture or with 0.1 mL of frozen inoculum (see 4.2.3). 3 
mL of this mixture were placed into each well of the deepwell plate. The cultivation 
was carried out at 30°C and 300 rpm for 7 days. 
 
4.2.2.2. Production of coumermycin A1 and its derivatives 
 
Cultivation in Erlenmeyer flasks 
 
For coumermycin A1 production, 5-10 mL of a TSB preculture of S. coelicolor M1146 
containing the entire or modified coumermycin gene cluster were used to inoculate a 
300 mL baffled Erlenmeyer flask containing 50 mL of SK medium, coumermycin 
production medium 1 (Weinstein et al., 1978) or coumermycin production medium 2 
(Kawaguchi et al., 1965). The cultivation was carried out at 30°C and 200 rpm for 7 
days. 
 
Cultivation in 24-square deepwell plates 
 
For cultivation in 24-square deepwell plates, 3 mL aliquots of the coumermycin 
production medium 1 (Weinstein et al., 1978) or 2 (Kawaguchi et al., 1965) were 
distributed to the wells of the deepwell plate. Each well was inoculated either with 75 
µL of fresh preculture or 15 µL of frozen inoculum of S. coelicolor M1146 containing 
the entire or modified coumermycin gene cluster. The cultivation was carried out at 
30°C and 300 rpm for 7 days. 
 
For the production of the CPM mono- and diamide, 40 mL of CDM medium were 
mixed with 0.2 mL of frozen inoculum of S. coelicolor M1146(couSS01) and 3 mL of 
this mixture were placed into each well of the 24-square deepwell plate. The 
cultivation was carried out at 30°C and 300 rpm for 6-7 days. 
 
4.2.2.3. Production of caprazamycins and liposidomycins 
 
For the production of caprazamycins and liposidomycins, 1 mL of a TSB preculture of 
the respective Streptomyces strain was used to inoculate a 300 mL baffled 
Erlenmeyer flask containing 50 mL of P medium. The cultivation was carried out at 
30°C and 210 rpm for 7 days. 
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4.2.3. Growth curves 
 
Growth curves were recorded either by measuring the optical density of the culture at 
600 nm or by determining the dry cell weight at different time points during the 
cultivation.  
 
4.2.3.1. Determination of optical density at 600 nm (OD600) 
 
1 mL of a YMG or TSB preculture was transferred to a 1 mL polystyrene cuvette and 
the optical density was measured at 600 nm using a spectrophotometer (Pharmacia 
LKB Novaspec II, Pharmacia, Freiburg/Germany). Samples were taken at different 
time points over 48 h of cultivation. During the growth phase (approx. after 12-24 h of 
cultivation) samples were taken every 2-3 hours. 
 
4.2.3.2. Determination of dry cell weight 
 
3 mL of CDM culture from a 24-square deepwell plate were filtered through a 
preweighted membrane filter with 0.45 μm pore size (Millipore Corporation, Billerica, 
MA, USA). The cells were washed with 10 mL of water and dried with the filters at 
80°C to constant weight. Samples were taken every 24 h for 7-10 days. 
 
 
4.2.4. Preparation of frozen inoculum 
 
For the preparation of frozen inoculum, the cells of a YMG or TSB preculture were 
harvested by centrifugation (10 min, 4°C, 2800 ×g) at an OD600 of 0.4-0.7. The cells 
were resuspended in 1/5 of the original culture volume of an aqueous solution of 
peptone 20% (w/v) and gently homogenized using a potter homogenizer operated 
manually (B. Braun Biotech, Sartorius AG, Göttingen, Germany). The resulting 
mixture was divided in aliquots of 1-2 mL and stored at -70°C. 
 
 
4.2.5. Preparation of spore suspensions 
 
For the preparation of spore suspensions Streptomyces strains were spread on MS 
agar and incubated at 30°C till dense sporulation was observed (about 1-2 weeks). 4 
mL of sterile ddH2O were added to each plate and the spores were scraped off of the 
top of the plates using a sterile cotton bud. The resulting spore suspension was 
poured into a falcon tube, vortexed and separated from the mycelium by passing 
through sterile cotton wool. After centrifugation (2100 xg, 4°C, 10 min) the spores 
were resuspended in 0.5-2.0 mL of glycerol solution 20% (v/v) and stored at -70°C. 
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5. Molecular biology methods 
 
Standard methods for DNA isolation and manipulation were performed as described 
by Kieser et al. (2000) and Sambrook & Russell (2001). 
 
5.1. DNA isolation 
5.1.1. Isolation of plasmid and cosmid DNA from E. coli 
 
Alkaline lysis was used to isolate recombinant plasmids and cosmids from E. coli 
(Sambrook & Russell, 2001). 3 mL LB medium were inoculated with a single colony 
and grown overnight at 37°C and 200 rpm. 1.5 mL of this culture was harvested by 
centrifugation (20000 xg, RT, 1 min) and the cells were resuspended in 100 µL 
solution MP1. The suspension was mixed with 200 µL solution MP2 by inversion and 
incubated on ice for 5 min (only for plasmid isolation). 150 µL solution MP3 was 
added and the mixture was incubated on ice for 5 min (only for plasmid isolation). 
After centrifugation (20000 xg, 4°C, 5 min) the supernatant was transferred to a fresh 
tube and the DNA was precipitated by addition of 500 µL isopropanol and 
centrifugation (20000 xg, 4°C, 30 min). The DNA pellet was washed with 500 µL 
ethanol 70% (v/v), air dried and resuspended in 50 µL Tris-HCl buffer (10 mM, pH 
8.0). The required solutions are listed in Table II.5.  
 
5.1.2. Isolation of genomic DNA from Streptomyces 
 
Genomic DNA was isolated by the following procedure. 2 mL of a 2-day-old culture in 
TSB medium were harvested by centrifugation (1500 xg, 4°C, 10 min). The cells 
were washed with 1 mL TSE buffer, resuspended in 500 µL TSE buffer with 
lysozyme (3 mg/mL) and RNase A (100 µg/mL) and incubated for 30 min at 37°C. 
250 µL of SDS solution were added and, after incubation for 10 min at 60°C, the 
mixture was vortexed vigorously for 1 min. 250 µL phenol/chloroform/isoamyl alcohol 
(25:24:1) were added and the mixture was vortexed vigorously for 1-2 min. After 
centrifugation (20000 xg, 4°C, 10 min) the supernatant was transferred to a fresh 
tube and, after addition of 150 µL TE buffer, was extracted for a second time with 250 
µL phenol/chloroform/isoamyl alcohol (25:24:1). The aqueous phase was separated 
and the genomic DNA was precipitated by addition of 70 µL NaOAc solution and 700 
µL isopropanol and centrifugation (20000 ×g, 4°C, 30 min). The DNA pellet was 
washed with 500 μL ethanol 70% (v/v), air dried and resuspended in 50 -100 μL Tris-
HCl buffer (10 mM, pH 8.0). The required solutions are listed in Table II.6. 
 
5.2. Purification, concentration and quantification of DNA 
 
Phenol/chloroform extraction and ion exchange chromatography were used for 
purification and ethanol or isopropanol precipitation for concentration of DNA.  
 
For quantification of DNA, a Nano Drop 1000 spectrophotometer (PeqLab, Erlangen, 
Germany) at 260 nm was used 
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5.3. DNA manipulation with enzymes 
 
Restriction of DNA with endonucleases was performed according to the 
manufacturers‟ instructions (New England Biolabs). 
 
DNA ligation was performed by using 1U T4-DNA ligase (New England Biolabs), 1x 
ligation buffer and the mixture of insert and linearized vector at a 1:1 ratio in a total 
volume of 10 μL. The mixture was incubated at 16°C overnight. 
 
5.4. PCR amplification of DNA 
 
PCR amplifications were carried out with a GenAmp® PCR system 2400 (Perkin-
Elmer, Weiterstadt, Germany). The primers listed in Table II.11 were purchased from 
Eurofins MWG (Ebersberg, Germany). Taq-DNA polymerase was used for all 
amplifications. 
 
For the purification of PCR products the QIAquick PCR Purification kit (Qiagen) was 
used and 5-10 µL of the purified PCR product were analysed by gel electrophoresis. 
 
 
Table II.12 General PCR reaction and amplification conditions 
 
Substance Final 
concentration 
10x amplification 
buffer 
1x 
Primer 50 pmol each 
Template about 100 ng 
dNTPs 0.2 mM each 
DNA polymerase 2.5 U 
DMSO 5 % (v/v) 
Final volume 50 µL 
 
 
5.5. Agarose gel electrophoresis of DNA 
 
Gel electrophoresis with 1% (w/v) agarose was used to separate DNA fragments 
between 0.25 and 10 kb. The buffer system employed was 1xTAE buffer (Table II.7). 
The gels were stained with ethidium bromide for 15 min and analysed under UV light 
(312 nm) using a gel documentation system from Biostep equipped with Argus X1 
software. 
 
 
 
 
 
 
Cyclus Temperature Time Cycles 
Hot start 94 °C 2 min 1 
Denaturing 94 °C 45 sec 
25-30 Annealing 50-60 °C 45 sec 
Elongation 72 °C 1 min 
Final 
elongation 
72 °C 5 min 1 
End 4 °C ∞ - 
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5.6. Introduction of DNA in E. coli and Streptomyces 
 
The methods described in this section were modified from Kieser et al. (2000) and 
Sambrook & Russell (2001). 
 
5.6.1. Introduction of DNA in E. coli 
5.6.1.1. Electroporation 
 
Preparation of electrocompetent cells 
 
50 mL LB medium were inoculated with 1 mL of an overnight culture of E. coli and 
cultivated at 37°C and 200 rpm till the OD600 reached 0.6 (2-4 h). The cells were 
harvested by centrifugation (3000 xg, 4°C, 5 min) and washed twice with 50 mL and 
25 mL ice-cold glycerol solution 10% (v/v), respectively. The supernatant was 
discarded and the cell pellet was suspended in the remaining drops. The competent 
cells could be used immediately or stored as 50 µL aliquots at -70°C. 
Electroporation 
 
1-3 µL DNA (about 100 ng) were mixed with 50 µL competent cells. The mixture was 
transferred into an ice-cold electroporation cuvette (0.2 cm) and electroporation was 
carried out using a BioRad electroporator set to 2.5 kV. The optimal time constant is 
4.5-5.0 ms. 1 mL ice-cold LB medium was immediately added to the cells and the 
suspension was transferred to a fresh tube. After incubation for 1 h at 37°C and 200 
rpm, 200 µL of the suspension were spread on LB agar containing the appropriate 
antibiotic(s). The agar plates were incubated overnight at 37°C. 
 
 
5.6.2. Introduction of DNA in Streptomyces 
5.6.2.1. Intergeneric conjugation 
 
Intergeneric conjugation was used to transfer modified plasmid DNA into 
Streptomyces. Therefore, the plasmid (containing an oriT) was introduced into the 
non-methylating E. coli strain ET12567/pUZ8002 harbouring the tra-genes required 
for mobilization and transfer of circular DNA. E. coli ET12567/pUZ8002 containing 
the plasmid was grown in LB medium supplemented with the appropriate antibiotic(s) 
at 37°C till the OD600 reached 0.6. The cells were harvested by centrifugation (3000 
xg, 4°C, 5 min) and washed twice with 20 mL ice-cold LB medium without antibiotics. 
The supernatant was discarded and the cell pellet was suspended in the remaining 
drops. 
 
In parallel 50 µL of spores of the target Streptomyces strain were incubated in 500 µL 
2xYT medium at 50°C for 10 min. The spore suspension was mixed with 500 µL of 
the E. coli ET12567/pUZ8002 suspension followed by centrifugation (3000 xg, 4°C, 2 
min). About 500 µL of the supernatant were discarded and the pellet was suspended 
in the remaining volume. Different volumes (20-100 µL) of the suspension were 
spread on MS agar supplemented with 10 mM MgCl2. After incubation at 30°C for 16-
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24 h, the plates were flooded with 1 mL sterile ddH2O containing the required 
antibiotics for selection of the mutants. Incubation was continued for further 3-7 days. 
 
Triparental conjugation was used for the transfer of modified cosmid DNA. Therefore, 
the cosmid DNA was introduced into E. coli ET12567 and cultivated as described 
above. In parallel E. coli ET12567/pUB307 was cultivated. After washing and 
resuspension of the cells, 500 µL of the Streptomyces spore suspension were mixed 
with 250 µL of each E. coli culture. 
 
 
6. Biochemistry methods 
6.1. Bioassay with Mycobacterium phlei 
 
Antibacterial activity of extracts, containing caprazamycins or liposidomycins, was 
determined by a disc diffusion assay using Mycobacterium phlei as the indicator 
strain. 10 μL methanolic culture extracts were applied to filter paper disks (Ø 6 mm; 
MN 440 B blotting paper, Macherey-Nagel), air dried under the clean bench and 
placed on the top of nutrient agar plates, which were spread with Mycobacterium 
phlei for confluent growth. Plates were cultured overnight at 37°C and the diameters 
of the growth inhibition zones were measured (Kaysser, 2010). 
 
 
7. Construction of Streptomyces mutant strains 
7.1. Deletion of couM-couN7 on cosmid couMW16 and heterologous 
expression 
 
A 7.1 kb fragment comprising the genes couM-couN7 was replaced on cosmid 
couMW16 by an apramycin resistance cassette using RED/ET mediated 
recombination (Gust et al., 2004), resulting in cosmid couMW22. The cassette for the 
replacement of couM-couN7 was generated by PCR using the primer pair couM_fwd 
and couN7_rev (Table II.11, Final report of Dr. Manuel Wolpert). The resistance 
cassette was removed by XbaI digestion and religation and the resulting cosmid 
couSS01 was introduced into S. coelicolor M1146 by triparental intergeneric 
conjugation with the help of E. coli ET12567/pUB307 (Flett et al., 1997) as described 
in section 5.6.2.1. Kanamycin resistant clones were selected, checked by PCR and 
designated S. coelicolor M1146(couSS01) 1-5. 
 
7.2. Deletion of couR1, couR2a, couR2b, couR3 and couR4 on cosmid 
couMW16 and heterologous expression 
 
The genes couR1, couR2a, couR2b, couR3 and couR4 were separately replaced on 
cosmid couMW16 by an apramycin resistance cassette using RED/ET mediated 
recombination. The resistance cassette was removed by XbaI/SpeI digestion and 
religation, resulting in the cosmids couAK06, couAK07, couAK08, couAK09 and 
couAK10, respectively (Knuplesch, 2008). The cosmids were introduced into S. 
coelicolor M1146 by triparental intergeneric conjugation with the help of E. coli 
32 II. MATERIALS AND METHODS   
 
ET12567/pUB307 as described in section 5.6.2.1. Kanamycin resistant clones were 
selected, checked by PCR and designated as S. coelicolor M1146(couAK06) 1-3, S. 
coelicolor M1146(couAK07) 1-2, S. coelicolor M1146(couAK08) 1-3, S. coelicolor 
M1146(couAK09) 1-3 and S. coelicolor M1146(couAK10) 1-3, respectively. 
 
7.3. Complementation of the ΔcouR1 and the ΔcouR4 mutant 
 
For the complementation of the ΔcouR1 and the ΔcouR4 mutant, the genes couR1 
and couR4 were amplified by PCR and the PCR products were cloned into pGEM-T 
(Promega), resulting in plasmids pAK01 (couR1) and pAK05 (couR4), respectively 
(Knuplesch, 2008). After digestion with HindIII and SpeI, couR1 and couR4 were 
cloned into the same sites of pUWL-Apra-oriT resulting in plasmids pAK06 and 
pAK10 (Knuplesch, 2008). pAK06 and pAK10 were introduced into S. coelicolor 
M1146(couAK06) and S. coelicolor M1146(couAK10), respectively, by intergeneric 
conjugation as described in section 5.6.2.1. Kanamycin resistant clones were 
selected, designated S. coelicolor M1146 (couAK06)/pAK06 1.1-1.5 and S. coelicolor 
M1146 (couAK10)/pAK10 1.1-1.5 and checked for coumermycin A1 production. 
 
 
8. Chemical synthesis 
8.1. Synthesis of 3-methylpyrrole-2,4-dicarboxylic acid 
 
3-methylpyrrole-2,4-dicarboxylic acid, the central pyrrole moiety (CPM) of 
coumermycin A1, was synthesized from its diethyl ester using a method described by 
Freel-Meyers et al. (2004). 
 
3-methylpyrrole-2,4-dicarboxylic acid diethyl ester (1.0 g, 4.44 mmol) and NaOH 
(1.76 g, 44.4 mmol) were solved in 60 mL of EtOH/H2O 1:1 (v/v) and heated to reflux 
overnight (16-18 h). After cooling to room temperature, 30 mL H2O were added, and 
the solution was acidified (pH 2) with HCl 37 % to precipitate the 3-methylpyrrole-2,4-
dicarboxylic acid. After 4 h at 4°C the precipitate was harvested by filtration, washed 
with ice-cold H2O and ice-cold acetone and dried under vacuum. The substance was 
subjected to 1H NMR analysis to confirm complete ester hydrolysis: 1H NMR (250 
MHz, DMSO-d6) δ 12.21 (s, 2 H, OH), 11.87 (m, 1 H, NH), 7.34 (d, 1 H, H-5), 2.46 (s, 
3 H, 3-Me) (see Appendix). 
 
 
9. Feeding experiments 
9.1. Feeding of 3-Methylpyrrole-2,4-dicarboxylic acid and O-Phospho-L-
threonine 
 
S. coelicolor M1146 containing the entire or modified coumermycin gene cluster was 
cultivated in coumermycin production medium 2 as described in section 4.2.2.2. 3-
methylpyrrole-2,4-dicarboxylic acid, O-phospho-L-threonine and L-threonine (negative 
control) were added to the cultures in two equal aliquots after 24h and 48h of 
cultivation, to give a final concentration of 0.1 mmol/L. 3-methylpyrrole-2,4-
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dicarboxylic acid was added as an ethanolic solution (15 mmol/L), O-phospho-L-
threonine and L-threonine as sterile aqueous solutions (15 mmol/L). The cultures 
were harvested after 7 days and the production of coumermycin A1 was determined 
by HPLC analysis. 
 
9.2. Feeding of 13C-labeled precursors 
 
S. coelicolor M1146(couSS01) was cultivated in CDM medium as described in 
section 4.2.2.3 (total culture volume: 360 mL). [U-13C,15N]L-threonine and [U-
13C]fumaric acid were added to the cultures as sterile aqueous solutions (64.5 
mmol/L and 34 mmol/L, respectively) in 5 equal aliquots after 72, 84, 96, 108 and 
120 h of cultivation, to give final concentrations of 2.15 mmol/L and 2.3 mmol/L, 
respectively. The cultures were harvested after 144 h of cultivation and the CPM 
monoamide was isolated from the culture as described in section 10.1.2.2. 
 
 
10. Analytical methods 
10.1. Sample preparation 
10.1.1. Novobiocin 
 
S. coelicolor M512(novBG01) was cultivated in CDM medium for 7 days as described 
in section 4.2.2.1. For analytical purposes 1 mL CDM culture was centrifuged twice 
(20000 xg, 4°C, 20 min) and the supernatant was directly used for HPLC analysis. 
 
10.1.2. Coumermycin A1 and its derivatives 
10.1.2.1. Coumermycin A1 
 
S. coelicolor M1146 containing the entire or modified coumermycin gene cluster was 
cultivated in SK medium, coumermycin production medium 1 or coumermycin 
production medium 2 for 7 days as described in section 4.2.2.2. For analytical 
puposes 1 mL culture was adjusted to pH 4 with 1N HCl and extracted three times 
with 600 µL ethyl acetate. The organic phase was evaporated and the residue 
resolved in 200 µL ethanol. If SK medium was used the culture was extracted with 
petroleum ether prior to extraction with ethyl acetate to remove the lard oil. 
 
10.1.2.2. CPM mono- and diamide 
 
S. coelicolor M1146(couSS01) was cultivated in CDM medium for 6-7 days as 
described in section 4.2.2.3. For analytical purposes 1 mL CDM culture was 
centrifuged twice (20000 xg, 4°C, 20 min) and the supernatant was directly used for 
HPLC and LCMS analysis. 
 
For preparative isolation of the CPM monoamide, the cultures were centrifuged (6000 
xg, RT, 30 min) and the cell pellet was discarded. The supernatant was adjusted to 
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pH 2 by addition of 1N HCl and left on ice for 30 min to precipitate the CPM 
monoamide, which was collected by centrifugation (4000 xg, 4°C, 15 min). After a 
washing step with ice cold 0.1N HCl, the precipitate was extracted three times with 6 
mL methanol and the insoluble material was discarded. The solvent was evaporated 
and the residue was resolved in 5 mL methanol at 70°C. Further purification of the 
CPM monoamide was achieved by semipreparative HPLC (see 10.2.2). 
 
10.1.3. Caprazamycins and liposidomycins 
10.1.3.1. Extraction of caprazamycins and liposidomycins 
 
Streptomyces sp. MK730-62F2 and Streptomyces sp. SN1061-M were cultivated in P 
medium as described in section 4.2.2.4. The culture supernatant was adjusted to pH 
4 by addition of 1N HCl and extracted twice with an equal volume of n-butanol. The 
organic phase was evaporated and the residue was resolved in 1 mL methanol. 
 
10.1.3.2. Affinity chromatography with Affi-Gel® boronate 
 
A cis-diol specific affinity chromatography was used for further purification of the 
extracts. Affi-Gel® boronate is a boronic acid stationary phase which specifically 
binds cis-diol structures, like the ribose of nucleosides, by formation of a cyclic 
boronate ester at alkaline pH values. At acidic pH values the ester bond is cleaved, 
resulting in the elution of the cis-diol-containing compounds (Bullinger et al., 2007). 
 
Preparation of the column 
 
500 mg Affi-Gel® boronate were suspended in ddH2O and the material was 
transferred to the column (150 x 15 mm) after 15 min of soaking. For conditioning of 
the column the scheme depicted in Table II.13 was used and the required buffers 
and solutions are listed in Table II.8. Compressed air was applied to maintain a 
moderate flow rate. 
 
Purification of caprazamycins and liposidomycins 
 
Caprazamycins and liposidomycins were extracted as described in section 10.1.3.1. 
300 µL of the culture extract were dissolved in 10 mL NH4OAc buffer (0.25 M, pH 8.8) 
and then loaded on the column, preconditioned with NH4OAc buffer (0.25 M, pH 8.8). 
After washing with NH4OAc buffer (0.25 M, pH 8.8) and MeOH/H2O 2:8 (v/v) elution 
was carried out with formic acid solution (0.2 M, MeOH/H2O 1:1 (v/v)), as shown in 
Table II.14. The solvent of the elution step was evaporated and the residue was 
dissolved in 1 mL methanol. The column can be stored on NaCl solution (0.1 M) at 4-
8°C for several weeks. 
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Table II.13 Conditioning of the column 
 
Step Buffer / Solution Volume 
1 H2O 10 mL 
2 MeOH/H2O 2:8 (v/v) 10 mL 
3 H2O 10 mL 
4 MeOH/H2O 2:8 (v/v) 10 mL 
5 H2O 10 mL 
6 NaCl solution 20 mL 
7 MeOH/H2O 2:8 (v/v) 30 mL 
8 Formic acid solution 30 mL 
9 NH4OAc buffer 30 mL 
10 MeOH/H2O 2:8 (v/v) 30 mL 
11 NH4OAc buffer 30 mL 
12 MeOH/H2O 2:8 (v/v) 30 mL 
13 Formic acid solution 30 mL 
14 MeOH/H2O 2:8 (v/v) 30 mL 
15 NaCl solution 50 mL 
 
 
 
Table II.14 Affinity chromatography for the purification of caprazamycins and liposidomycins 
(optimized method) 
 
Step  Buffer / Solution Volume 
1 Preconditioning NH4OAc buffer (0.25 M, pH 8.8) 45 mL 
2 Sample Culture extract  
NH4OAc buffer (0.25 M, pH 8.8) 
0.3 mL 
10 mL 
3 Washing step 1 NH4OAc buffer (0.25 M, pH 8.8) 20 mL 
4 Washing step 2 MeOH/H2O 2:8 (v/v) 6 mL 
5 Elution Formic acid solution (0.2 M)  50 mL 
6 Regeneration MeOH/H2O 2:8 (v/v) 25 mL 
 
 
10.2. HPLC analysis 
 
For HPLC analysis a Agilent 1200 system with PDA detector or a Agilent 1100 
system with VWD detector, both equipped with ChemStation software for data 
recording and evaluation, were used. A Reprosphere® C18-DE column (5 µm, 3 x 
150 mm) with a flow rate of 0.6 mL/min or a Reprosphere® C18-DE colum (5 µm, 4.6 
x 150 mm) with a flow rate of 1.0 mL/min were used for analytical purposes and a 
Multosphere® 120 RP18 column (5 µm, 250 x 8 mm) with a flow rate of 1 mL/min was 
used for preparative HPLC. 
 
10.2.1. Novobiocin 
 
For analysis of novobiocin, the conditions depicted in Table II.15 were used. 
Authentic novobiocin was used as standard. 
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Table II.15 HPLC conditions for novobiocin analysis 
 
Time 
[min] 
Solvent A 
[%] 
Solvent B 
[%] 
Flow rate Wavelength Temperature 
0.0 40 60 
1 mL/min 305 nm not controlled 
2.0 40 60 
13.0 0 100 
19.0 0 100 
19.1 40 60 
25.0 40 60 
Solvent A: H2O : HCOOH (99:1) 
Solvent B: CH3OH : HCOOH (99:1)  
 
 
10.2.2. Coumermycin A1 and its derivatives 
 
For analysis of coumermycin A1 and its derivatives, the conditions depicted in Table 
II.16 were used. For all coumermycin derivatives authentic coumermycin A1 was 
used as standard, only for the CPM monoamide authentic novobiocin was used. For 
the preparative isolation of the CPM monoamide, the conditions depicted in Table 
II.17 were used 
 
 
Table II.16 HPLC conditions for coumermycin A1 analysis  
 
Time 
[min] 
Solvent A 
[%] 
Solvent B 
[%] 
Flow rate Wavelength Temperature 
0.0 30 70 
0.6 mL/min 345 nm 40°C 
2.0 30 70 
22.0 0 100 
26.0 0 100 
26.1 30 70 
30.0 30 70 
Solvent A: H2O : HCOOH (99:1) 
Solvent B: CH3CN : HCOOH (99:1) 
 
 
Table II.17 HPLC conditions for the purification of CPM monoamide 
 
Time 
[min] 
Solvent A 
[%] 
Solvent B 
[%] 
Flow rate Wavelength  Temperature 
0.0 60 40 
1 mL/min 345 nm not controlled 
5.0 60 40 
25.0 0 100 
30.0 0 100 
31.0 60 40 
35.0 60 40 
Solvent A: H2O : HCOOH (99.9:0.1) 
Solvent B: CH3CN : HCOOH (99.9:0.1)  
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10.3. LCMS analysis 
 
For LC/ESI-MS analysis, a Thermo Finnigan TSQ Quantum triple-stage quadrupole 
mass spectrometer (Thermo Finnigan, San Jose, USA) coupled to a Surveyor HPLC 
system was used. Reversed-phase chromatography was carried out on a Reprosil-
Pur® Basic C18 column (5 µm, 250 x 2 mm) at a flow rate of 0.2 mL/min. The mobile 
phase consisted of (A) water/formic acid (99.9:0.1) and (B) acetonitrile/formic acid 
(99.9:0.1). Mass spectrometry settings for electrospray ionization (ESI) in positive 
and negative mode are shown in Table II.18. 
 
Table II.18 Mass spectrometry settings 
 
Parameter Positive mode Negative mode 
 caprazamycins caprazamycins coumermycins 
Electrospray voltage 3.8 kV - 4.0 kV - 3.8 kV 
Heated capillary temperature 320°C 320°C 300°C 
Collision gas argon argon argon 
Collision gas pressure 1.0 mTorr 1.0 mTorr 1.0 mTorr 
Sheath/auxillary gas nitrogen nitrogen nitrogen 
Sheath gas pressure 30 Arb 35 Arb 35 Arb 
Auxillary gas pressure 12 Arb 10 Arb 10 Arb 
 
 
10.3.1. Coumermycin A1 and its derivatives 
10.3.1.1. HPLC conditions 
 
The HPLC conditions for the LCMS analysis of coumermycin A1 and its derivatives 
are listed in Table II.19. 
 
Table II.19 HPLC conditions for coumermycin A1 and its derivatives.  
 
Time 
[min] 
Solvent A [%] Solvent B [%] Flow rate Wavelength 
0.0 98 2 
0.2 mL/min 345 nm 
5.0 98 2 
30.0 0 100 
39.0 0 100 
40.0 98 2 
45.0 98 2 
Solvent A: H2O : HCOOH (99.9:0.1) 
Solvent B: CH3CN : HCOOH (99.9:0.1) 
 
10.3.1.2. MS/MS product ion scans 
 
Product ion scans were performed in negative ionization mode on the respective [M-
H]- ions of coumermycin A1 and its derivatives, e.g. CPM mono- and diamide. The 
collision energy was set to 40V for coumermycin A1 and 25V for CPM mono- and 
diamide, respectively. Argon was used as collision gas. Product ion spectra were 
recorded with a scan time of 0.7 s for each mass and a peak width of 0.7 for the first 
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quadrupole (Q1) and the third quadrupole (Q3), respectively. The mass range was 
set according to the m/z values of the molecular ion and the expected fragment ions. 
 
10.3.2. Caprazamycins and liposidomycins 
10.3.2.1. HPLC conditions 
 
The HPLC conditions for the LCMS analysis of caprazamycins and liposidomycins 
are listed in Table II.20. 
 
Table II.20 HPLC conditions for caprazamycins and liposidomycins 
 
Time 
[min] 
Solvent A [%] Solvent B [%] Flow rate Wavelength 
0.0 98 2 
0.2 mL/min 261 nm 
5.0 98 2 
9.0 70 30 
38.0 0 100 
45.0 0 100 
46.0 98 2 
50.0 98 2 
Solvent A: H2O : HCOOH (99.9:0.1) 
Solvent B: CH3CN : HCOOH (99.9:0.1) 
 
10.3.2.2. MS/MS product ion scans 
 
In positive ionization mode product ion scans were performed on the respective 
[M+H]+ ions of the caprazamycins and liposidomycins and in negative ionization 
mode on the respective [M–H] – ions. The collision energy was set to 35V in positive 
mode and 30V in negative mode. Product ion spectra were recorded with a scan time 
of 0.7 s for each mass and a peak width of 0.7 for the first quadrupole (Q1) and the 
third quadrupole (Q3), respectively. The mass range was set according to the m/z 
values of the molecular ion and the expected fragment ions. 
 
10.3.2.3. MS/MS precursor ion scan 
 
Precursor ion spectra of the permethylated L-rhamnose at m/z 189 in positive mode 
were obtained by scanning the mass range m/z 150–1500. Spectra were recorded 
with a scan time of 0.7 s and a collision energy of 35V. 
 
10.4. NMR analysis 
 
For NMR analysis the compounds were dissolved in d6-dmso and NMR spectra were 
recorded on spectrometer Varian Inova 500 equipped with 13C-sensitive cryoprobe 
(1H: 500 MHz, 13C: 125.7 MHz) or on Bruker AMX 600 (1H: 600 MHz, 13C: 
156.7 MHz). Chemical shifts in d6-dmso are reported as δ values relative to the 
respective solvent as an internal reference. 
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III. RESULTS 
 
1. Antibiotic production in 24-square deepwell plates 
 
Investigations on antibiotic formation in streptomycetes are often hampered by the 
notorious variability of production rates observed between successive and even 
between parallel cultivation batches of the same strain in Erlenmeyer flasks. A 
cultivation method which shows less variability in secondary metabolite production 
therefore would significantly reduce the workload and cost of research in antibiotic 
biosynthesis. 
 
1.1. Comparison of novobiocin production in Erlenmeyer flasks and 24-
square deepwell plates 
 
In a first experiment, the novobiocin production of S. coelicolor M512(novBG01) in a 
24-square deepwell plate with sandwich-cover, as described by Duetz and co-
workers (Duetz, 2007; Duetz & Witholt, 2004), was compared to that in baffled 
Erlenmeyer flasks equipped with a stainless steel spring. The polypropylene plate 
contained 24 square wells (18x18 mm in the horizontal plane, 40 mm deep) and each 
well was filled with 3 mL of liquid medium while the Erlenmeyer flasks each contained 
50 mL (Figure III.1A). Both, deepwell plate and Erlenmeyer flasks, were inoculated 
with the same batch of fresh preculture, cultivated in YMG medium, and the cultures 
were agitated on orbital shakers (25 mm shaking diameter) at 300 and 200 rpm, 
respectively. As shown in Figure III.1B, novobiocin production after 7 days was 
higher in the Erlenmeyer flasks (24 mg/L vs. 11 mg/L) but the variability was much 
lower in the deepwell plate (relative standard deviation 39% and 6%, respectively).  
 
 
Figure III.1 
Comparison of novobiocin production in 
Erlenmeyer flasks and a 24-square deepwell 
plate. A) Cultures of S. coelicolor M512 
(novBG01) in Erlenmeyer flask and deepwell 
plate. B) Novobiocin production and variability 
in 10 Erlenmeyer flasks and 10 wells of a 
deepwell plate in a parallel cultivation. 
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1.2. Optimization of the inoculation method 
 
In order to further reduce the variability of novobiocin production in the 24-square 
deepwell plates, especially between independent cultivation batches, the inoculation 
method was optimized. This involved the optimization of the inoculation ratio with and 
without homogenization of the inoculum and preparation of frozen inoculum either 
from the early stationary phase or from a defined section of the growth phase. 
 
1.2.1. Homogenization of the preculture and optimization of the inoculation 
ratio 
 
As Streptomyces cultures with their mycelial growth form cell aggregates of variable 
size in liquid culture, it was tested whether homogenization of the preculture with a 
potter homogenizer prior to mixing with the fresh medium would further reduce 
variability. Therefore the appropriate amount of homogenized or non-homogenized 
preculture of S. coelicolor M512(novBG01) was mixed with the fresh medium and 
then 3 mL aliquots of this mixture were dispensed to the wells of the deepwell plates. 
Since pre-mixing of inoculum and fresh medium may bear a certain risk of unequal 
inoculation due to sedimentation of cells in the mixture, separate dispensing of 
medium and homogenized inoculum to the deepwell plates was also tested. 
However, all of these method variations resulted in similar antibiotic production and 
similar variability (rel. SD 2.0 – 4.7%). Subsequently, the inoculation ratio, i.e. the 
ratio of preculture volume to production medium volume, was varied from 1:20 to 
1:160, using both homogenized and non-homogenized inoculum. Using non-
homogenized inoculum the highest novobiocin production was obtained with an 
inoculation ratio of 1:40 (Figure III.2). As may be expected, homogenized inoculum 
with its higher number of colony-forming units could be used in a slightly smaller 
amount (1:80), but the difference between the two ratios was small. An inoculation 
ratio of 1:80 was therefore used in all further experiments. 
 
 
Figure III.2  
Influence of the inoculation ratio on novobiocin 
production in S. coelicolor M512(novBG01) in 
24-square deepwell plates. A) Direct 
inoculation with the preculture and B) Inocu-
lation with homogenized inoculum using a 
potter homogenizer. During homogenization, 
cells from 5 Vol preculture were resuspended 
in 1 Vol production medium or peptone 
solution 20% (w/v). Inoculation volumes were 
adjusted accordingly. 
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1.2.2. Use of frozen inoculum and preparation of inoculum from a defined 
section of the growth phase 
 
In order to provide a uniform inoculum for a series of experiments over a range of 
time, a large batch of frozen inoculum which could be stored at -70°C was prepared, 
following the procedure described in the materials and methods section (4.2.4). This 
procedure involves centrifugation of the preculture, resuspension of the cells in 20% 
(w/v) peptone as cryoprotectant, gentle homogenization with a potter homogenizer 
and freezing at -70°C. Freezing and re-thawing of an inoculum of S. coelicolor 
M512(novBG01) did not affect novobiocin production (Figure III.3) and independent 
cultivation experiments from the same batch of frozen inoculum over a period of nine 
months showed standard deviations of 8 % between different time points, and 4% to 
9% within parallel experiments at the same time point. However, when different 
batches of precultures from the same strain were used, the variability between these 
experiments was found to be high (53 % relative standard deviation). Harvesting of 
the precultures in a defined section of the growth phase might reduce this batch-to-
batch variability. 
 
The growth curve of S. coelicolor M512(novBG01) in 50 mL YMG medium in a 300 
mL baffled Erlenmeyer flask with stainless steel spring was recorded by monitoring 
the optical density at 600 nm over 48 hours (Figure III.4). Rapid growth occurred 
between 12 and 20 hours after inoculation when OD600 values rose quickly from 0.3 
to 0.7. The final OD600 after 48 hours was 0.8. Five independent batches of frozen 
inoculum were prepared from precultures harvested at OD600 values between 0.5 and 
0.7 and, notably, novobiocin production between cultures, prepared from these five 
different batches, varied only by 6% (relative standard deviation), i.e. much less than 
using inocula from the early stationary phase. Also the absolute novobiocin 
production (30 mg/L) was higher than using inoculum from the early stationary 
phase. Harvesting of the precultures in the second half of the growth phase therefore 
is clearly of advantage. The precise time when the OD value is reached varied 
slightly from flask to flask, but the range from OD600 0.5 - 0.7 proved large enough to 
conveniently obtain cultures at the desired growth stage. It was not necessary to 
make adjustments from the slight differences in cell density of the homogenized 
inoculum batches as such adjustments did not reduce variability of the novobiocin 
production any further. 
 
 
 
Figure III.3 
Effect of freezing of the mycelial inoculum 
of S. coelicolor M512(novBG01) (in the 
presence of 20% (w/v) peptone) on 
novobiocin production 
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Figure III.4 
Growth curve of S. coelicolor 
M512(novBG01) in YMG medium 
 
 
1.3. Influence of aeration on novobiocin production 
 
One reason for the originally lower novobiocin production in the deepwell plates, in 
comparison to Erlenmeyer flasks (Figure III.1B), may be insufficient aeration. To 
increase aeration, sandwich covers with 4 mm holes instead of 2 mm ones were 
tested. However, this did not cause a difference in the novobiocin production, in 
accordance with previous observations that not aeration of the headspace but gas–
liquid transfer is limiting for oxygen supply of the culture (Duetz et al., 2000; Duetz & 
Witholt, 2001; Duetz & Witholt, 2004). All further experiments therefore were carried 
out with the standard sandwich covers with 2 mm holes. However, a smaller culture 
volume should lead to better aeration of the culture due to the increased 
surface/volume ratio. Indeed novobiocin production in 1.5 mL culture volume was 
slightly higher than in 3 mL (5.5 versus 4.5 mg/L), but so was the standard deviation 
(14.5 versus 6.2%). A culture volume of 3 mL was therefore used in all further 
experiments, and alternative methods were explored to increase oxygen supply, e.g. 
the addition of an artificial oxygen carrier. 
 
1.4. Investigation of a siloxylated ethylene oxide/propylene oxide 
copolymer as artificial oxygen carrier 
 
Oxygen carriers, such as the natural compound haemoglobin or the 
biotechnologically used perfluorodecalin, can be used to increase the concentration 
of oxygen in aqueous solutions and improve the efficiency of oxygen-consuming 
biochemical processes. Siloxylated ethylene oxide/propylene oxide copolymers such 
as Q2-5247, which are water-soluble compounds in contrast to perfluorodecalin, 
have recently been shown to increase growth of Bacillus thuringensis and production 
of the polyketide antibiotic actinorhodin in S. coelicolor A3(2) (Dey et al., 2004). 
Therefore the effect of the addition of the copolymer Q2-5247 on novobiocin 
production in S. coelicolor M512(novBG01) was tested. When this compound was 
added to the medium in concentrations between 0.3% and 2.4%, a strong increase of 
novobiocin production was observed. The most effective concentration was found to 
be 0.6%, which led to a 5-fold overproduction of novobiocin in comparison to the 
control (Figure III.5). Production rates in the deepwell plates supplemented with Q2-
5247 were comparable to those observed in Erlenmeyer flasks. Cell growth and 
novobiocin production were compared with and without the addition of polymer over 
a culture period of 10 days (Figure III.6). This showed that the copolymer did not 
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influence cell growth. Notably, the cell aggregates were smaller in the presence of 
Q2-5247, and novobiocin production started 1 day earlier (Figure III.6). 
 
 
Figure III.5 
Optimization of the final concentration of 
the siloxylated ethylene oxide/propylene 
oxide copolymer Q2-5247 for S. 
coelicolor M512(novBG01) in the 
novobiocin production medium 
 
 
 
 
 
 
 
 
 
Figure III.6 
A) Growth curves and B) 
production curves of an frozen 
inoculum of S. coelicolor M512 
(novBG01) without copolymer 
and with addition of 0.6% 
siloxylated ethylene oxide/ 
propylene oxide copolymer Q2-
5247 
 
 
 
 
 
 
 
 
 
 
 
 
1.5. Overexpression of the pathway-specific positive regulator novG 
 
Another possibility to increase novobiocin production is the overexpression of novG, 
a pathway-specific positive regulator of novobiocin biosynthesis. In Erlenmeyer 
flasks, overexpression of this gene was already shown to increase novobiocin 
production (Eustáquio et al., 2005) and when cultures of S. coelicolor M512 
(novBG01) harbouring the novG expression plasmid pAE12 were compared with 
those containing the empty vector pWHM3 in the 24-square deepwell plates, a three-
fold increase of novobiocin production was observed. Furthermore, the positive 
effects of novG and of copolymer Q2-5247 on novobiocin production could be 
combined. By simultaneous copolymer addition and novG expression an 11-fold 
increase of novobiocin formation was achieved, reaching 163 mg/L and thereby 
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exceeding all previous production levels observed in Erlenmeyer flasks in our 
laboratory (Figure III.7). 
 
 
Figure III.7 
Effect of overexpression of the positive 
regulator novG and the addition of 0.6% 
of the siloxylated ethylene oxide/ 
propylene oxide copolymer Q2-5247 on 
novobiocin production in S. coelicolor 
M512(novBG01); pAE12: novG 
expression plasmid; pWHM3: empty 
vector 
 
 
 
 
 
 
1.6. Production of coumermycin A1 and derivatives thereof in the 24-
square deepwell plates 
 
Since the suitability of 24-square deepwell plates for investigations on antibiotic 
production in Streptomyces was now demonstrated at the example of novobiocin, it 
was decided, that this method should also be used for the investigation of the 
biosynthesis of the central pyrrole moiety (CPM) of coumermycin A1, described in the 
following chapter. However, SK medium, which was originally used for coumermycin 
production, was not suitable for cultivations in the deepwell plates, due to the lard oil 
contained therein. Therefore, two previously described production media without lard 
oil, in this thesis termed coumermycin production medium 1 (Weinstein et al., 1978) 
and 2 (Kawaguchi et al., 1965), were tested. 
 
In a previous study the coumermycin gene cluster was assembled into a single 
construct, termed couMW16, and then this construct was integrated into the ΦC31 
attachment site of the genome of S. coelicolor M512. The resulting mutants produced 
on average 7 mg/L coumermycin A1, exceeding the productivity of the wild-type 
producer strain Streptomyces rishiriensis DSM 40489 under the same cultivation 
conditions (5 mg/L) (Flinspach et al., 2010; Wolpert et al., 2008). For unknown 
reasons, coumermycin production suddenly dropped dramatically (< 1 mg/L) at the 
beginning of this study and therefore it was decided to use the recently developed 
host strain S. coelicolor M1146 for the heterologous expression of cosmid couMW16 
(Gomez-Escribano & Bibb, 2011). The average coumermycin A1 production of the 
resulting strain in SK medium, using baffled Erlenmeyer flasks as the cultivation 
system, was 52 mg/L (SD = 16.9 mg/L), 7.5 times higher than the average 
productivity originally found in S. coelicolor M512 containing the same cosmid 
(Flinspach et al., 2010). 
  
Cultivation of S. coelicolor M1146(couMW16) in medium 1 (Weinstein et al., 1978) 
led to a total coumermycin production of 19 mg/L. However, the main product was 
not coumermycin A1 but coumermycin C, containing only one terminal pyrrole moiety 
which additionally lacks the methyl group at position 5 (Figure III.8 and III.9). Besides 
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these two compounds, significant amounts of coumermycin A2, B and D-1b/1c were 
detected, also lacking one of the terminal pyrrole moieties and/or one or both methyl 
groups (Figure III.8 and III.9). Since the methylation reaction catalysed by CouN6 is 
methylcobalamine-dependent (Westrich et al., 2003), supplementation of the medium 
with 0.2 mg/L cobalt chloride, as in SK medium, should be able to shift the production 
to coumermycin A1 (Claridge et al., 1966). As shown in Figure III.9, production of 
coumermycin A1 was indeed significantly increased after the addition of cobalt 
chloride (4 mg/L vs. 0.6 mg/L) although an influence on the total coumermycin 
production was not observed (17 mg/L vs. 19 mg/L). However, coumermycin A1 was 
still not the main product but coumermycin B (11 mg/L). Therefore it was decided to 
test a second production medium, which is more similar to the originally used SK 
medium. 
 
In production medium 2 (Kawaguchi et al., 1965), also supplemented with 0.2 mg/L 
cobalt chloride, the total coumermycin production was significantly higher than in 
medium 1 (53 mg/L vs. 17 mg/L). Additionally, with an average production of 36 
mg/L, coumermycin A1 was now the main product (Figure III.9). Therefore, 
production medium 2 was used in all further experiments, except for the production of 
the CPM mono- and diamide (Figure III.10), where CDM medium was used.  
 
The inoculation ratio was varied from 1:5 to 1:160, using a homogenized inoculum of 
S. coelicolor M1146(couSS01). The differences in the production between the tested 
ratios were small (4.5 - 6.5 mg/L of CPM diamide) and a ratio of 1:40 was chosen for 
all further experiments. Since the growth curve of S. coelicolor M1146(couSS01) in 
TSB medium looked similar to that of S. coelicolor M512(novBG01) shown in Figure 
III.4, frozen inocula were also prepared from precultures harvested at OD600 values 
between 0.5 and 0.7. 
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Figure III.8 
Chemical structures of coumermycins A-D. In case of coumermycin B and C isomeric 
structures, i.e. the terminal pyrrole moiety at the other deoxysugar moiety, are possible 
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Figure III.9 
Test of two different media for coumermycin production with and without addition of cobalt 
chloride (0.2 mg/L). Medium 1: coumermycin production medium 1 (Weinstein et al., 1978); 
Medium 2: coumermycin production medium 2 (Kawaguchi et al., 1965). 
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2. Biosynthesis of the central 3-methylpyrrole-2,4-dicarboxylic 
acid moiety of coumermycin A1 
 
Coumermycin A1 contains two types of pyrrole moieties, i.e. a 3-methylpyrrole-2,4-
dicarboxylic acid moiety (hereafter called the central pyrrole moiety, Figure III.10A) 
and two 5-methylpyrrole-2-carboxylic acid groups (hereafter called the terminal 
pyrrole moieties), which are also found in clorobiocin (Figure III.10A). While the 
terminal pyrrole moieties are formed from L-proline by action of CouN1-7 and most of 
the reaction steps involved have been investigated in vitro (Balibar et al., 2007; 
Fridman et al., 2007; Garneau-Tsodikova et al., 2006; Garneau et al., 2005; Walsh et 
al., 2006), the biosynthetic pathway to the central pyrrole moiety is still unknown.  
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Figure III.10 
A) Chemical structures of the aminocoumarin antibiotics novobiocin, clorobiocin, 
coumermycin A1, coumermycin D, of the central pyrrole moiety (CPM), of CPM diamide and 
CPM monoamide. B) The biosynthetic gene cluster of coumermycin A1. The genes 
investigated in this study for their participation in the biosynthesis of the central pyrrole 
moiety are shaded in grey. 
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2.1. The genes couN1-couN7 are not involved in the biosynthesis of the 
central pyrrole moiety of coumermycin A1 
 
Previous inactivation experiments in the genuine coumermycin producer strain had 
shown that couN3 and couN4 are not required for the biosynthesis of the central 
pyrrole moiety (CPM) of coumermycin A1 (Xu et al., 2002). We now carried out a 
deletion of all seven genes involved in the biosynthesis and transfer of the terminal 
pyrrole moieties of coumermycin, i.e. of the entire region from couN1 to couN7. In 
order to ease analysis of the products, we decided to delete at the same time the 
gene couM, adjacent to couN1 (Figure III.11). couM codes for the glycosyl 
transferase which is responsible for the transfer of the deoxysugar moiety to the 
aminocoumarin ring (Freel Meyers et al., 2004). Deletion of couM is therefore 
expected to result in accumulation of the coumermycin aglycone (CPM diamide, 
Figure III.10A) and possibly its immediate precursor, CPM monoamide (Figure 
III.10A). Both compounds have been identified previously as enzymatic reaction 
products of the amide synthetase CouL (Schmutz et al., 2003b).  
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Figure III.11 
Deletion of the genes couN1-couN7 responsible for the formation of the terminal pyrrole 
moieties of coumermycin A1. couM codes for the glycosyltransferase attaching the 
deoxysugars of coumermycin. Genes couM-couN7 were replaced on cosmid couMW16 by 
an apramycin resistance cassette, resulting in cosmid couMW22. Removal of the resistance 
cassette resulted in cosmid couSS01.  
 
 
Integration of the coumermycin biosynthetic gene cluster (contained in cosmid 
couMW16) into the ΦC31 attachment site of the genome of Streptomyces coelicolor 
M1146 results in heterologous production of coumermycin A1 (Flinspach et al., 2010; 
Gomez-Escribano & Bibb, 2011; Wolpert et al., 2008). We now replaced the 7.1 kb 
fragment comprising the genes couM-couN7 on cosmid couMW16 by an apramycin 
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resistance cassette, using RED/ET mediated recombination (Gust et al., 2003). This 
initial work was conducted by Dr. Manuel Wolpert and resulted in cosmid couMW22 
(Figure III.11). To avoid a possible polar effect of the inactivation on downstream 
genes, the resistance cassette was removed by digestion with XbaI and religation. 
Originally, digestion with XbaI and SpeI was planned to remove the resistance 
cassette, but the SpeI site got lost during recombination. Therefore, the resulting 
cosmid couSS01 contained a “scar” sequence of 49 bp instead of 6 bp, which 
resulted in a frame-shift and the loss of the couN7 stop codon. However, the frame-
shift also resulted in another stop codon, located in the intergenic region upstream of 
couO. Hence cosmid couSS01 was introduced into S. coelicolor M1146 by 
conjugation and the genotype of the integration mutant was verified by PCR.  
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Figure III.12 
Production of CPM monoamide and CPM diamide by S. coelicolor M1146(couSS01). A) 
HPLC-UV analysis of the culture supernatant. B) HPLC-MS extracted ion chromatograms 
(EIC) showing CPM monoamide (m/z 357) and CPM diamide (m/z 546). C) Collision-induced 
dissociation (CID)-MS/MS spectra. See Figure VI.2 in the Appendix for suggested structural 
formulas of the mass spectrometric fragments.  
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When S. coelicolor M1146(couSS01) was cultured in the production medium CDM, 
CPM diamide and CPM monoamide were readily detected after seven days by 
HPLC-UV and HPLC-MS analysis in 4 mg/L and 12 mg/L yield, respectively (Figure 
III.12). Since both compounds contain the complete central pyrrole moiety of 
coumermycin A1, this experiment provided conclusive evidence that none of the 
genes from couN1 to couN7 is required for the formation of CPM (and neither is 
couM). Therefore, the pathways to the central and the terminal pyrrole moieties of 
coumermycin do not share the same biosynthetic enzymes. 
 
2.2. The genes couR1-couR4 are involved in the biosynthesis of the 
central pyrrole moiety of coumermycin 
 
The genes couR1-couR4 within the coumermycin biosynthetic gene cluster do not 
have orthologs in the gene clusters of novobiocin or clorobiocin, and their function is 
yet unknown. By comparison to database entries, these genes were originally 
annotated as hypothetical protein (couR1), decarboxylase (couR2), threonine kinase 
PduX (couR3) and dehydrogenase (couR4) (Wang et al., 2000). The predicted 
product of couR2 was a 377 aa protein. However, renewed sequencing of cosmid 
couMW16 proved that the original sequence AF235050 was incorrect: one nucleotide 
(i.e. C24843) needed to be deleted. This results in a TGA stop codon 5 bp 
downstream of the deleted cytidine. A putative GTG start codon overlaps with this 
stop codon (GTGA, stop codon underlined). Therefore, this DNA region codes for two 
proteins, i.e. CouR2a (172 aa) and CouR2b (205 aa). Database comparison shows 
several decarboxylases (e.g. sulfopyruvate decarboxylase) consisting of an α- and a 
β-subunit which closely correspond in sequence and size to CouR2a and CouR2b. 
Therefore, we corrected the sequence AF235050 in GenBank. 
 
The five genes couR1, couR2a, couR2b, couR3 and couR4 were separately replaced 
on cosmid couMW16 by an apramycin resistance cassette, using RED/ET mediated 
recombination (Gust et al., 2003). This work was done by Anna Knuplesch and is 
described in detail in her diploma thesis (Knuplesch, 2008). In case of couR3 and 
couR4 the complete open reading frame was replaced, leaving only the start and 
stop codon intact. In case of couR1, couR2a and couR2b an internal sequence, 
comprising approximately half of each gene, was replaced, because the start and/or 
stop codons of these genes overlap and a complete replacement may have affected 
the presumed translational coupling. The resistance cassette was removed in all 
cases by digestion with XbaI and SpeI and religation, leaving only a 6 bp “scar” 
sequence.  The resulting integrative cosmids, termed couAK06 – couAK10, were 
introduced into S. coelicolor M1146 by conjugation and the genotype of the mutants 
was verified by PCR. 
 
Three independent clones of each mutant (two independent clones in case of 
ΔcouR2a) were cultivated and coumermycin A1 production was determined by HPLC-
UV and HPLC-MS analysis. Strain S. coelicolor M1146(couMW16), harbouring the 
intact gene cluster, was used as positive control. The results are shown in Table III.1. 
Deletion of couR1 and couR4 led to the total abolishment of coumermycin A1 
production. Deletion of couR2a, couR2b and couR3 reduced coumermycin A1 
production by 99.8 %, 92% and 99% in comparison to the reference strain, but 
HPLC-UV and HPLC-MS analysis still showed a residual production of the antibiotic.  
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We speculated that genes of the expression host compensated for the gene 
deletions to some extent, allowing the residual coumermycin A1 production. Indeed, a 
BLAST search revealed that the genome of the expression host Streptomyces 
coelicolor contains orthologs of couR2a/2b and couR3, i.e. sco6824 (NP_733715) 
similar to couR2a/2b and sco0991 (NP_625287) similar to couR3.  
 
The ΔcouR1 and ΔcouR4 mutants were complemented with intact copies of the 
deleted genes, cloned into replicative expression vectors (see Materials and 
Methods). The respective plasmids pAK06 and pAK10 were constructed by Anna 
Knuplesch and are also described in her diploma thesis (Knuplesch, 2008). 
Coumermycin A1 production was restored by the complementation, but only to 2-3 % 
of the production level found in the reference strain, S. coelicolor M1146(couMW16). 
Low production rates in complemented mutants are encountered frequently and may 
be due to e.g. incorrect regulation of the gene expression, or to problems of protein 
folding or protein interactions. 
 
2.3. Feeding of the central pyrrole moiety to the deletion mutants 
 
The above described inactivation experiments showed that the genes couR1-couR4 
are involved in the biosynthesis of coumermycin A1, but did not prove that they are 
involved specifically in the biosynthesis of the central pyrrole moiety. In order to show 
that these genes are responsible for the biosynthesis of the central pyrrole moiety, 3-
methylpyrrole-2,4-dicarboxylic acid was added to the cultures of the mutants after 
24h and 48h of cultivation, to give a final concentration of 0.1 mmol/L (i.e. 16.9 mg/L). 
Coumermycin production was restored by this external feeding in the ΔcouR1, 
ΔcouR2b, ΔcouR3 and ΔcouR4 mutants (Table III.1). In the ΔcouR2a mutant, 
production was increased under external feeding by a factor of ten, but still remained 
lower than in the other strains. The reason for this is unknown, but we noticed that 
only few integration mutants could be obtained using the ΔcouR2a cosmid, and the 
obtained mutants showed relatively slow growth. 
 
These results provided evidence that the four genes couR1, couR2b, couR3 and 
couR4, and probably also couR2a, are involved in the biosynthesis of the central 
pyrrole moiety of coumermycin A1. 
 
 
Table III.1 
Restoration of coumermycin A1 production in gene deletion mutants by feeding of the central 
pyrrole moiety (CPM)  
 
[a] n.d. = not determined 
 
 coumermycin A1 [mg/L] 
 no CPM added + CPM (16.9 mg/L) 
intact gene cluster 10.20 n.d.[a] 
ΔcouR1 < 0.01. 3.8 
ΔcouR2a 00.02 0.2 
ΔcouR2b 00.80 5.1 
ΔcouR3 00.10 6.6 
ΔcouR4 < 0.01. 5.0 
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2.4. Feeding of O-Phospho-L-threonine to the ΔcouR3 mutant 
 
CouR3 (302 aa) shows similarity to kinases of the GHMP family, e.g. 34% identity to 
the threonine kinase PduX involved in adenosyl-cobalamine biosynthesis in 
Salmonella enterica (Fan & Bobik, 2008; Fan et al., 2009). We therefore speculated 
that the biosynthesis of the central pyrrole moiety of coumermycin may possibly 
involve an O-phosporylation of threonine. Fan and Bobik (2008) were able to show 
that feeding of O-phospho-L-threonine to a pduX defective mutant of Salmonella 
enterica was able to compensate for the growth defect caused by the deletion of 
pduX. Therefore, we tested whether feeding of O-phospho-L-threonine to the ΔcouR3 
mutant could restore the production of coumermycin A1. 
 
O-Phospho-L-threonine was added to the cultures of three independent clones of the 
couR3 defective mutant after 24h and 48h of cultivation, to give a final concentration 
of 0.1 mmol/L. In a parallel experiment, L-threonine was fed as control. Four 
independent replicates were carried out for each experiment. However, the results 
were not fully conclusive (Table III.2): feeding of O-phospho-L-threonine reproducibly 
increased coumermycin production, but only from 0.137 to 0.197 mg/L (i.e. by 44 %). 
In contrast, feeding of L-threonine had no significant effect on coumermycin 
production. Though this experiment showed a positive effect of O-phospho-L-
threonine on coumermycin production in the ΔcouR3 mutant, the effect is too small in 
order to provide strong support for a role of O-phospho-L-threonine in the 
biosynthesis of CPM.  
 
 
Table III.2 
Coumermycin A1 production of the ΔcouR3 mutant after feeding of L-threonine (Thr) and O-
phospho-L-threonine (Thr-P) 
 
clone[a] 
ΔcouR3 ΔcouR3 + Thr ΔcouR3 + Thr-P 
mean 
(mg L-1) 
SD 
(mg L-1) 
mean 
(mg L-1) 
SD 
(mg L-1) 
mean 
(mg L-1) 
SD 
(mg L-1) 
1 0.14 (100%) 0.05 0.16 (114%) 0.03 0.24 (171%) 0.08 
2 0.15 (100%) 0.07 0.14 (93%) 0.03 0.17 (113%) 0.05 
3 0.12 (100%) 0.01 0.13 (108%) 0.01 0.18 (150%) 0.02 
average 0.137 (100%) 0.143 (104%) 0.197 (144%) 
[a] Three independent clones were generated of the ΔcouR3 strain Streptomyces coelicolor 
M1146(couAK08). Four independent feeding experiments were carried out for each clone, 
and mean and standard deviation (SD) of these experiments are reported.  
 
 
2.5. Intact incorporation of [U-13C,15N]L-threonine into the central 
pyrrole moiety of coumermycin 
 
The sequence similarity of CouR3 to a threonine kinase and the above feeding 
experiment with O-phospho-L-threonine hinted at the possibility that L-threonine may 
be a precursor of the central pyrrole moiety of coumermycin A1. To provide 
unambiguous proof, we carried out a feeding experiment with [U-13C,15N]L-threonine, 
followed by MS and NMR analysis. To ease the investigation of the coupling patterns 
in NMR analysis, we used the above described heterologous expression strain 
containing the construct couSS01 (Figure III.11) and isolated the produced CPM 
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monoamide (MR = 358.3, Figure III.10A), instead of using a strain producing 
coumermycin A1 (MR = 1110.1, Figure III.10A). NMR analysis and data evaluation 
were in all cases conducted by Nadja Burkard (AK Grond, Organic Chemistry 
Department, University of Tübingen). 
 
Initially, unlabeled monoamide was isolated from cultures of S. coelicolor 
M1146(couSS01) in an amount of 8.3 mg from two successive cultivations, and the 
13C-NMR signals of this compound were assigned by 2D-NMR methods (see 
Appendix). The CPM monoamide was isolated as a pure regioisomer, with the 
aminocoumarin moiety linked to the carboxyl group at position 4 of the pyrrole ring 
(Figure III.14).  
 
In a preliminary, small-scale feeding experiment, [U-13C,15N]L-threonine was added to 
6 mL culture volume, using a 24-square deepwell plate for cultivation (Siebenberg et 
al., 2010). The culture supernatant was analysed by HPLC-MS in comparison to 
cultures without feeding of labeled threonine (Figure III.13). The CPM monoamide 
formed in the feeding experiment showed a strong MS signal with m/z 362 [M-H]-, 
additionally to the regular molecular ion (M-H- = 357, Figure III.13). This fragment 
(M-H+5) indicated that the four 13C carbons and the 15N nitrogen of the labeled L-
threonine had been incorporated into the CPM monoamide. The fragmentation 
pattern of the m/z 362 ion showed m/z 206, i.e. the unlabeled aminocoumarin ring, as 
the most abundant fragment, demonstrating that the label had been incorporated into 
the pyrrole rather than into the aminocoumarin moiety. 
 
 
 
Figure III.13 
Incorporation of [U-13C,15N]L-
threonine into CPM monoamide, 
shown by mass spectrometric 
analysis. Mass spectra A) of the 
unlabeled CPM monoamid and B) of 
the labeled CPM monoamide. C) 
CID-MS/MS spectrum of the labeled 
CPM monoamide. The expected 
positions of the label are indicated by 
asterisks. For the CID-MS/MS 
spectrum of the unlabeled CPM 
monoamide see Figure III.12. 
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Figure III.14 
Expected fragmentation of the two possible 
regioisomers of CPM monoamide labeled by 
feeding of [U-13C,15N]L-threonine.  
Experimentally, the [M-H]– = 232 fragment was 
observed (see Figure III.13), indicating that the 
CPM monoamide has the upper structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The exact regiochemistry of the incorporation of the labeled L-threonine was 
determined by 13C-NMR spectroscopy of CPM monoamide isolated from a 
subsequent large-scale experiment. Therefore, [U-13C,15N]L-threonine (96 mg; final 
concentration 2.15 mmol/L) was added to 360 mL of growing cultures of S. coelicolor 
M1146(couSS01) in five 24-square deepwell plates (see Materials and Methods). 
The cultures were harvested six days after inoculation, and cells were removed by 
centrifugation. The culture medium was acidified to pH 2.0, resulting in the 
precipitation of the monoamide. This was collected by centrifugation, dissolved in 
methanol and purified by preparative HPLC (yield 2.1 mg). NMR analysis and data 
evaluation were then conducted by Nadja Burkard (AK Grond, Organic Chemistry 
Department, University of Tübingen). The 13C-NMR spectrum (Figure III.15) showed 
an average isotope enrichment of 19.5 % for pyrrole carbons C-2, C-3, C-6 and C-7. 
The clear coupling pattern with 1JC-C, 
2JC-C and JC-N couplings (Table III.3) proved 
unequivocally that the intact carbon skeleton and the nitrogen of [U-13C,15N]L-
threonine were incorporated into the CPM monoamide (Figure III.16). Therefore, the 
above mentioned four carbon atoms and the ring nitrogen of the central pyrrole 
moiety of coumermycin A1 are derived from threonine. A conversion of threonine to 
proline does not occur in general amino acid metabolism. Accordingly, proline is not 
the precursor of the central pyrrole moiety of coumermycin A1, but the producing 
organism uses two different biosynthetic pathways towards the central and the 
terminal pyrrole moieties of the antibiotic.  
 
A second feeding experiment with [U-13C]fumaric acid was conducted to identify the 
second precursor of CPM. Unfortunately, no 13C-enrichment was observed in the 
NMR analysis of the isolated CPM monoamide. Therefore, fumaric acid is probably 
not a precursor of CPM. However, fumaric acid was only used because no 13C-
labeled oxaloacetate, the postulated second precursor (Figure IV.2), was available. 
We expected fumaric acid to be converted to oxaloacetate in the citric acid cycle via 
maleic acid, which also is a probable precursor of CPM (Berg et al., 2011). 
 
232
233
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Figure III.15 
13C-NMR analysis of the incorporation of [U-13C,15N]L-threonine into CPM monoamide (125.7 
MHz, d6-DMSO, cold probe). Expansions of 
13C-NMR coupling patterns of all enriched 
pyrrole carbon atoms with respective coupling constants (in Hz). Structural fragments with 
respective couplings. 
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Table III.3 
13C NMR chemical shifts and enrichment ratios of CPM monoamide, isolated after feeding of 
[U-13C,15N]L-threonine in d6-DMSO 
 
Carbon δC (ppm)
[b] JCC (Hz)
[c] JCN (Hz) Enrichment (%)
[d] 
C-2 120.6 86.3 (C-6) 
68.9 (C-3) 
02.6 (C-7) 
 
│13.7│ 20 
C-3 127.8 68.9 (C-2) 
46.0 (C-7) 
06.0 (C-6) 
 
│3.8│ 19 
C-4 118.0 [a] [a] [a] 
C-5 125.5 [a] 
 
[a] [a] 
C-6 162.4 86.3 (C-2) 
06.0 (C-3) 
 
│3.0│ 19 
C-7 011.2 46.0 (C-3) 
02.6 (C-2) 
 
│0.5│ 20 
C-8 160.9 [a] [a] [a] 
C-2‟ 164.8 [a] [a] [a] 
C-3‟ 100.5 [a] [a] [a] 
C-4‟ 159.3 [a] [a] [a] 
C-5‟ 121.5 [a] [a] [a] 
C-6‟ 111.9 [a] [a] [a] 
C-7‟ 158.9 [a] [a] [a] 
C-8‟ 110.3 [a] [a] [a] 
C-9‟ 151.2 [a] [a] [a] 
C-10‟ 108.3 [a] [a] [a] 
C-11‟ 008.1 [a] [a] 1.8 
[a] not detected. [b] Chemical shifts were referenced to residual DMSO. [c] coupling partners 
are shown in parentheses. [d] Method for the calculation of enrichment is shown in the 
Appendix 
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Figure III.16 
13C enrichment in CPM monoamide after feeding of [U-13C,15N]L-threonine. 
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3. Identification and structural elucidation of new caprazamycins 
from Streptomyces sp. MK730-62F2 by LC/ESI-MS/MS 
 
For the identification of new caprazamycin and liposidomycin derivatives, e.g. 
resulting from inactivation experiments, a rapid and precise analytical method is 
required that also supplies sufficient structural information. High-performance liquid 
chromatography coupled to a triple-stage quadrupole mass spectrometer is capable 
of both, separating complex mixtures of secondary metabolites and providing reliable 
information on the analyte‟s mass and structure. 
 
3.1. Identification of caprazamycins A-G and of liposidomycin A in 
culture extracts of the respective producer strains 
 
Caprazamycins and liposidomycins are structurally complex compounds showing 
acidic as well as basic functional groups (Figure III.17). Therefore, the liquid 
chromatography/electrospray ionization mass spectrometry (LC/ESI-MS) analysis 
was conducted both in positive and in negative ionization mode, using culture 
extracts of the caprazamycin producer strain Streptomyces sp. MK730–62F2 and the 
liposidomycin producer strain Streptomyces sp. SN-1061M. The [M+H]+ and [M–H]- 
ions of the caprazamycins A–G and liposidomycin A (Figure III.17) were readily 
detected in the extracts, showing that both positive and negative ionization mode are 
suitable for the analysis of those compounds.  
 
 
G
R1
A
B
C
D
E
F
caprazamycins
R2
A
B
C
Z
H
G
L
M
K
N
liposidomycins (+)-caprazol  
 
Figure III.17 
Chemical structures of caprazamycins, liposidomycins and (+)-caprazol. The structural 
differences between caprazamycins and liposidomycins are shaded in grey. 
58 III. RESULTS   
 
The collision-induced dissociation (CID) MS/MS spectra of the caprazamycins A–G 
and liposidomycin A were recorded in positive and negative ionization mode as well. 
Caprazamycins and liposidomycins show a characteristic fragmentation pattern, 
which reflects the structural similarities as well as the structural differences of the 
analysed compounds (Figure III.18 and Table VI.1, see Appendix). The product ions 
formed by CID of the [M+H]+ and [M–H]- precursor ions can be divided into two 
groups. Product ions from the first group show distinctive m/z values for the different 
caprazamycins or liposidomycins, respectively, according to the differences in the 
mass of the fatty acid side chain. Product ions from the second group lack the fatty 
acid side chain and are therefore characteristic for all caprazamycins and/or 
liposidomycins. Characteristic product ions in positive ionization mode for both 
caprazamycins and liposidomycins, with m/z 558 and m/z 427, result from the 
successive loss of the fatty acid side chain and of the aminoribose. Product ions with 
m/z 320 and m/z 189 are only present in the mass spectra of caprazamycins, since 
liposidomycins lack the permethylated L-rhamnose moiety (Figure III.17). Further 
product ions, m/z 1002, m/z 813 and m/z 701 in the case of caprazamycin C, derive 
from the loss of the aminoribose and of the uracil prior to the loss of the fatty acid 
side chain. For the liposidomycins the first step in the fragmentation pathway seems 
to be the loss of the sulfate group, which is consistent with the published fast atom 
bombardment mass spectrometry (FAB-MS) data (Kimura et al., 1998b; Ubukata et 
al., 1988). In negative ionization mode characteristic fragments resulted from the 
successive loss of the fatty acid, of the carboxyl group at the caprazol and of the 
aminoribose with m/z values of 556, 512 and 363, respectively. Since the loss of the 
sulfate group occurs less frequently in negative mode, characteristic product ions 
with m/z 636 and 592 can be found in the mass spectra of the liposidomycins. The 
sulfated product ions show higher relative intensities than the corresponding non-
sulfated product ions (2% for m/z 636 vs. <0.1% for m/z 556 and 100% for m/z 592 
vs. <0.1% for m/z 512), which can be explained by the good ionization of the sulfate 
group in negative mode. Product ions containing the fatty acid and the 3-
methylglutaryl moiety can also be detected as well as the fatty acid side chain alone.  
 
3.2. Purification of culture extracts by affinity chromatography 
 
The samples used in this study were derived from the extraction of the acidified 
culture supernatant with n-butanol. However, not only the caprazamycins or 
liposidomycins were extracted by that but a wide range of culture components which 
could interfere with the caprazamycins during HPLC and LC/MS analysis. Affi-Gel® 
boronate is a boronic acid-containing gel which specifically binds cis-diol structures, 
like the ribose of nucleosides, by formation of a cyclic boronate ester at alkaline pH 
values. At acidic pH values the ester bond is cleaved, resulting in elution of the cis-
diol-containing compounds. Since caprazamycins and liposidomycins contain a 
nucleosidic structure, purification by the described method should be possible. The 
protocol used was modified from Bullinger et al. (2007) and is shown in Table III.5.  
 
A bioactivity assay with Mycobacterium phlei showed the highest bioactivity for 
washing step 2 (6 mL methanol/water 1:1 (v/v)), comparable to the bioactivity of the 
unpurified culture extract (Figure III.19A). It was confirmed later by LC/ESI-MS/MS 
analysis that the caprazamycins already eluted in the second washing step and not in 
the elution step.  
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Figure III.18 
Characteristic CID-MS/MS spectra of caprazamycin C from Streptomyces sp. MK730–62F2 
and liposidomycin A from Streptomyces sp. SN-1061M in A) positive and B) negative 
ionization mode with the suggested fragmentations. The collision energy applied was 35V for 
positive and 30V for negative ionization mode, respectively. 
 
60 III. RESULTS   
 
However, after the washing step was changed to 6 mL of methanol/water 2:8 (v/v) 
the caprazamycins eluted, as desired, in the following elution step with 0.2 M formic 
acid in methanol/water 1:1 (v/v) (Figure III.19B). The colour of the extract changed 
visibly after affinity chromatography from dark red to light yellow and the peaks of the 
caprazamycins in the Q3 full scan, between 16 and 25 minutes, became more 
distinct. Additionally, the inconsistent broad peak at about 13 minutes significantly 
decreased (Figure III.20). Interestingly, the Q3 full scan showed more peaks 
between 16 and 25 min than there are known caprazamycins and therefore, a scan 
for new caprazamycins was conducted. 
 
 
Table III.5 
Affinity chromatography with Affi-Gel® boronate. Comparison of the original method modified 
by Bullinger et al. (2007) and the optimized method for the purification of caprazamycins and 
liposidomycins. 
 
Step 
 Buffer / Solution 
Volume  Original method 
(Bullinger et al., 2007) 
Optimized method 
1 Preconditioning NH4OAc buffer  
(0.25 M, pH 8.8) 
NH4OAc buffer  
(0.25 M, pH 8.8) 
45 mL 
2 Sample Culture extract (0.3 mL) 
in NH4OAc buffer  
(0.25 M, pH 8.8) 
Culture extract (0.3 mL) 
in NH4OAc buffer  
(0.25 M, pH 8.8) 
10 mL 
3 Washing step 1 NH4OAc buffer  
(0.25 M, pH 8.8) 
NH4OAc buffer  
(0.25 M, pH 8.8) 
20 mL 
4 Washing step 2 MeOH/H2O 1:1 (v/v) MeOH/H2O 2:8 (v/v) 6 mL 
5 Elution Formic acid solution (0.2 
M)  
Formic acid solution (0.2 
M)  
50 mL 
6 Regeneration MeOH/H2O 1:1 (v/v) MeOH/H2O 2:8 (v/v) 25 mL 
 
 
. 
Figure III.19  
Bioactivity assay with Mycobacterium phlei 
after purification of the caprazamycins by 
affinity chromatography with Affi-Gel® 
boronate. A) Original method modified by 
Bullinger et al. (2007) and B) optimized 
method. 1: culture extract (unpurified); 2: 
sample flow through; 3: washing step 1; 4: 
washing step 2; 5: eluate; 6: regeneration 
of the column (see Table III.5 for details) 
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Figure III.20 
Mass chromatograms of Q3 full scans before and after purification of the culture extract by 
affinity chromatography on a boronic acid gel (optimized method). The peaks of the 
caprazamycins can be found at retention times between 16 and 25 min. 
 
3.3. Identification of new caprazamycins 
 
The search for new caprazamycins was performed by precursor ion scans in positive 
ion mode with m/z 558, 427, 320 and 189 and in negative ion mode with m/z 333 and 
363. Precursor ion scans allow the identification of new derivatives from a known 
structural class of compounds by scanning for characteristic product ions. Besides 
the known caprazamycins A–G with m/z 1146.6, 1132.6 and 1118.5 six new 
compounds with m/z 1114.5, 1116.5, 1142.5, 1144.6, 1170.6 and 1172.6 were 
detected in the precursor ion scans with m/z 189 (permethylated L-rhamnose) 
(Figure III.21) and 320 (3-methylglutaryl moiety + permethylated L-rhamnose; data 
not shown) but not with the two other product ions. The same result was achieved in 
negative ion mode with m/z 333 and 363 (data not shown). The CID-MS/MS spectra 
of the six new compounds in positive ionization mode show the typical fragmentation 
pattern of the caprazamycins (Figure III.22 and III.23) and the mass differences to 
the known caprazamycins suggest the incorporation of mono and di-unsaturated fatty 
acids. In rising order of retention time these new caprazamycins were termed 
caprazamycin H, I, J, K, L and M. Complete structural elucidation of their fatty acid 
moieties was not possible with the available mass spectrometric instrumentation, but 
the proposed chemical formula fit that of the fatty acid moieties from the 
liposidomycins Y, Z, A, G, K and N, respectively (Figure III.21 and Table VI.2, see 
Appendix). Since there could be several fatty acids with the same chemical formula 
the caprazamycins H–M could each consist of not only one but several compounds. 
A full structural elucidation of the fatty acid side chains will therefore be mandatory. 
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Figure III.21 
A) Precursor ion scan with 
m/z 189 (L-rhamnose 
moiety) and B) extracted ion 
chromatograms (EIC) of the 
new caprazamycins (CPZ) 
H–M with the suggested 
fatty acid residues (R1) 
found in the liposido-
mycins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.22 
Fragmentation scheme of 
the caprazamycins H–M in 
positive mode. The CID-
MS/MS spectra of the new 
caprazamycins are shown 
in Figure III.23. 
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Figure III.23 
CID-MS/MS spectra of the six new caprazamycins in positive ionization mode: A) 
caprazamycin H (m/z 1114.5), B) caprazamycin I (m/z 1116.5), C) caprazamycin J (m/z 
1142.5), D) caprazamycin K (m/z 1144.6), E) caprazamycin L (m/z 1170.6) and F) 
caprazamycin M (m/z 1172.6). The fragmentation scheme is presented in Figure III.22. 
 
 
64 IV. DISCUSSION   
 
IV. DISCUSSION 
 
1. Antibiotic production in 24-square deepwell plates 
 
Investigations on antibiotic formation in Streptomyces are often hampered by the 
notorious variability of production rates observed between successive and even 
between parallel cultivation batches of the same strain in Erlenmeyer flasks (Minas et 
al., 2000). Often these flasks are equipped with a baffle and/or a stainless steel 
spring in order to increase aeration and to reduce the size of cell aggregates which 
are formed by the hyphal growth of the streptomycetes. However, this also leads to 
splashing of the liquid medium and to wall growth of the cells, probably contributing to 
the problem of variability (Betts & Baganz, 2006; Büchs, 2001). The high standard 
deviation in the production rates makes it necessary to increase the number of 
parallel cultures if significant differences need to be distinguished from chance 
variations. This increases both, the workload and the demand for shakers, flasks, 
media and analytical equipment. A cultivation method which shows less variability in 
secondary metabolite production therefore would significantly reduce the workload 
and costs of research in antibiotic biosynthesis.  
 
Micro-culture systems based on various designs of microtiter plates have been 
investigated in the past few years as an alternative system to Erlenmeyer flasks 
(Duetz, 2007; Duetz et al., 2000; Minas et al., 2000). However, previous 
investigations mostly focused on bacteria with unicellular dispersion and on the 
determination of growth and primary metabolism. Only a single study has been 
published previously on the cultivation of streptomycetes in such a culture system, 
investigating growth and production of the polyketide antibiotic actinorhodin (Minas et 
al., 2000). Recently, the utilization of 24-square deepwell plates has been adopted 
for systems biology research in Streptomyces coelicolor (Prashant M. Bapat, 
personal communication). Based on these methods, the production of the 
aminocoumarin antibiotic novobiocin was investigated in the heterologous producer 
strain S. coelicolor M512(novBG01) which has been generated by site-specific 
integration of the entire novobiocin biosynthetic gene cluster into the genome of the 
host strain (Eustáquio et al., 2005). 
 
In the present study it was shown, that 24-square deepwell plates provide a very 
suitable system for investigations on the production of novobiocin in the heterologous 
producer strain. Compared to Erlenmeyer flasks, the main advantage of this system 
is the low variability (4–9%) of novobiocin production rates between parallel cultures, 
as well as the low requirement for shaker space and culture medium. Furthermore, 
handling of the deepwell plates is faster than that of Erlenmeyer flasks, and can be 
automated. Therefore, the use of 24-square deepwell plates may help to reduce the 
costs and the workload of investigations on antibiotic production in microorganisms.  
 
Under the conditions used in this study, novobiocin production rates in the deepwell 
plates were originally lower than in the Erlenmeyer flasks (Figure III.1B), probably 
due to insufficient aeration. It was shown by Duetz and co-workers (Duetz et al., 
2000; Duetz & Witholt, 2001; Duetz & Witholt, 2004) that gas–liquid transfer rather 
than aeration of the headspace is the limiting factor for oxygen supply in the cultures 
and therefore the use of sandwich covers with bigger holes (4 mm instead of 2 mm) 
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had no effect on the production of novobiocin. However, artificial oxygen carriers 
such as the water soluble compound Q2-5247, a siloxylated ethylene 
oxide/propylene oxide copolymer, are able to increase the concentration of oxygen in 
aqueous solutions and improve the efficiency of oxygen-consuming biochemical 
processes. Accordingly, the addition of Q2-5247 resulted in an increase of growth of 
Bacillus thuringensis and of the production of the polyketide antibiotic actinorhodin in 
S. coelicolor A3(2) (Dey et al., 2004). In the present study, inclusion of 0.6% of 
copolymer Q2-5247 was able to significantly enhance the production of novobiocin, 
presumably by increasing the oxygen supply to the cells. An alternative way to 
increase the oxygen supply may have been an increase of shaker speed (currently 
300 rpm) or shaker diameter (25 mm). However, the commonly available commercial 
shakers operate with 25 mm shaking diameter and do not allow speeds significantly 
above 300 rpm.  
 
The deepwell plates offer a convenient system e.g. to investigate the influence of 
external factors like media components on antibiotic production or for feeding 
experiments with biosynthetic precursors. In such studies, it is preferable to use the 
same batch of inoculum for all experiments, resulting in the best reproducibility of 
production rates. As long as the precultures used as inoculum were harvested in the 
early stationary phase we were not successful in obtaining reproducible novobiocin 
production between independently prepared batches of (genetically identical) 
inoculum, even when the homogenized inoculum mixture was standardized for the 
optical density or for the number of colony-forming units. However, reproducible 
novobiocin production values between independently prepared batches of inoculum 
could be readily obtained when the cells of the preculture were harvested in a 
defined section of the growth phase. These inocula also resulted in higher novobiocin 
production than inocula from the stationary phase, which is in accordance with 
previous findings on clavulanic acid production (Neves et al., 2001). It is well known 
that in the transition from growth phase to stationary phase, bacterial cultures 
undergo fundamental changes in the gene expression pattern which have a profound 
effect on secondary metabolite production (Bibb, 2005). This may contribute to the 
variability between independent batches of inoculum harvested in the early stationary 
phase. It is therefore preferable to harvest precultures in a defined section of the 
growth phase and this procedure appears mandatory when antibiotic production is to 
be compared between genetically different mutant or transformant strains. 
 
The production of coumermycin A1 in the 24-square deepwell plates required a new 
production medium, since the originally used SK medium was not suitable due to the 
lard oil contained therein. However, cultivation of the heterologous producer stain S. 
coelicolor M1146(couMW16) in the tested media resulted in the production of not 
only coumermycin A1 but of several coumermycin derivatives, e.g. coumermycin A2, 
lacking the methyl groups at position 5 of the terminal pyrrole moieties (Claridge et 
al., 1984; Claridge et al., 1966). The methyltransferase CouN6, which is responsible 
for the methylation of the terminal pyrrole moieties, is methylcobalamine-dependent 
(Westrich et al., 2003). Therefore, the addition of cobalt chloride to the tested 
production media was able to shift coumermycin production in favour of coumermycin 
A1 (Claridge et al., 1966). 
 
Although this study was originally prompted by the need for a production system with 
low variability for investigations on the regulatory genes of aminocoumarin antibiotic 
formation in the heterologous producer strains (Dangel et al., 2008; Eustáquio et al., 
66 IV. DISCUSSION   
 
2005), 24-square deepwell plates are now widely used in our laboratory, e.g. for the 
investigation of the biosynthesis of the central pyrrole moiety of coumermycin A1 
described in this thesis or for the comparison of genetically modified Streptomyces 
coelicolor strains as hosts for the heterologous production of aminocoumarin and 
liponucleoside antibiotics (Flinspach et al., 2010). 
 
 
2. Biosynthesis of the central 3-methylpyrrole-2,4-dicarboxylic 
acid moiety of coumermycin A1 
 
Coumermycin A1 contains two types of pyrrole moieties, i.e. two terminal 5-methyl-
pyrrole-2-carboxylic acid moieties and the central 3-methylpyrrole-2,4-dicarboxylic 
acid moiety. While the pyrrole-2-carboxylate scaffold of the terminal pyrrole moieties 
can be found in several other natural products (Walsh et al., 2006), the 3-
methylpyrrole-2,4-dicarboxylic acid moiety is to our knowledge unique. 
 
The electron-rich, planar pyrrole ring system is an important structural element in 
many biomolecules of primary and secondary metabolism. It can coordinate metals, 
form hydrogen bonds and provide stacking interactions (Walsh et al., 2006). The 
best-known pathway for pyrrole biosynthesis proceeds via δ-aminolevulinic acid to 
the porphyrins. Another important route is the dehydrogenation of L-proline to pyrrole-
2-carboxyl units. That route leads to the terminal pyrrole moieties of coumermycin A1 
and clorobiocin (Figure III.10A), but also to one of the three pyrrole rings found in the 
prodiginines of Streptomyces and Serratia species. The biosynthesis of the terminal 
pyrrole moieties of coumermycin A1 from L-proline is catalysed by CouN1-7 and 
involves the activation of L-proline by thioester formation with an acyl carrier protein, 
the oxidation to the pyrrole, the methylation at position 5 and the transfer to the 
deoxysugar moiety in a two-step acyl transfer process (Figure IV.1). These and other 
enzymatic machineries for the biological formation of pyrroles have been reviewed by 
Walsh et al. (2006). The present study now reveals a further, hitherto unknown 
pathway to a pyrrole ring system. While the terminal pyrrole moieties of coumermycin 
A1 are derived from L-proline, the central pyrrole moiety (CPM) is not. Inactivation of 
the genes couN1-couN7 proved that none of the enzymes involved in the formation 
and transfer of the terminal pyrrole moieties is required for the biosynthesis of the 
central pyrrole moiety. Rather, inactivation experiments followed by feeding of CPM 
established that the genes couR1, couR2a/b, couR3 and couR4 are involved in the 
formation of CPM (Table III.1). 
 
Heterologous expression of the cosmid couSS01 (Figure III.11) resulted in the 
formation of CPM monoamide and CPM diamide, indicating that all enzymes required 
for the biosynthesis of CPM are encoded in couSS01. In detailed previous studies, 
the function of all genes contained in couSS01 in biosynthesis, regulation and self-
resistance has been elucidated (Heide, 2009), except for the genes couR1-couR6. 
The gene product of couR5 shows similarity to transporters of the major facilitator 
superfamily (Schmutz et al., 2003a), and the gene product of couR6 is similar to 
transcriptional regulators of the LysR family. Therefore, these two genes are not likely 
to code for biosynthetic enzymes, but the genes couR1-couR4 may encode all 
enzymes required for the assembly of the central pyrrole moiety. 
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Figure IV.1 
Biosynthesis and transfer of the terminal pyrrole moiety of coumermycin A1 from L-proline by 
action of CouN1-CouN7. Modified from Heide (2009). 
 
 
CouR3 (302 aa) shows sequence similarity to the threonine kinase PduX involved in 
adenosyl-cobalamine biosynthesis in Salmonella enterica (Fan et al., 2009). The 
biosynthesis of the central pyrrole moiety of coumermycin A1 may therefore involve 
the O-phosporylation of threonine. In case of CouR1 (474 aa), BLAST searches 
revealed only five proteins in the database with significant similarity and all of these 
are annotated as hypothetical proteins. However, the PHYRE server (Kelley & 
Sternberg, 2009) indicated a similarity of CouR1 to “tryptophan synthase beta-subunit 
like PLP-dependent enzymes” (SCOP 53686). Tryptophan synthase catalyzes the 
replacement of the OH-group of serine with an indole moiety, resulting in L-
tryptophan (Dunn et al., 2008). CouR2a (172 aa) and CouR2b (205 aa) show 
similarity to many thiamine pyrophosphate-dependent decarboxylases. Some of 
these consist of two subunits which correspond in sequence and size to the separate 
proteins CouR2a and CouR2b, e.g. the sulfopyruvate decarboxylase ComDE from 
Methanococcus jannaschii (Graupner et al., 2000), some others include both 
subunits in a single polypeptide chain (Zhang et al., 2003). ComDE is a dodecamer 
consisting of six alpha (D) and six beta (E) subunits and catalyses the 
decarboxylation of sulfopyruvic acid to sulfoacetaldehyde in the coenzyme M 
pathway (Graupner et al., 2000). CouR4 (389 aa) shows similarity to many FMN-
dependent dehydrogenases. 
 
This study unequivocally proved that L-threonine is incorporated intact into CPM and 
provides the heterocyclic nitrogen as well as four of the seven carbons of this moiety. 
It is tempting to speculate that the biosynthesis of CPM may start from L-threonine 
(Figure IV.2), and that the first step in this pathway may be the formation of O-
phospho-L-threonine catalysed by CouR3, identical to the reaction catalysed by PduX 
in adenosyl-cobalamine biosynthesis in Salmonella enterica (Fan et al., 2009). 
However, feeding of O-phospho-L-threonine to a couR3 defective mutant increased 
coumermycin production only by 44 %, i.e. to a level of  0.2 mg/L (Table III.2), while 
feeding of CPM to the same mutant increased coumermycin production >50-fold, i.e. 
to a level of 6.6 mg/L (Table III.1). This may indicate that L-threonine first forms 
another intermediate, e.g. a Schiff's base with a compound containing a carbonyl 
group, and that the hydroxyl group of threonine is phosphorylated in a later step. On 
the other hand, O-phospho-L-threonine is a very polar compound which may not 
easily be taken up into the cell, and is also easily hydrolysable by phosphatases. This 
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may provide an alternative explanation for the relatively small increase of 
coumermycin A1 production after feeding of O-phospho-L-threonine. Notably, in a 
total of 12 feeding experiments with this compound coumermycin production was 
consistently higher than observed after feeding of free threonine (Table III.2). 
Therefore, our results do not exclude that O-phospho-L-threonine may be an 
intermediate in the biosynthesis of the central pyrrole moiety of coumermycin. 
 
 
 
 
Figure IV.2 
Hypothetical biosynthetic pathway to the central pyrrole moiety of coumermycin A1 (i.e. 3-
methylpyrrole-2,4-dicarboxylic acid). 
 
 
The biosynthetic origin of the other three carbons of CPM is unknown. Figure IV.2 
shows oxaloacetate as a hypothetical precursor of this part of the molecule, with 
CouR1 catalysing a ß-replacement of the hydoxyphosphate group of O-phospho-L-
threonine, followed by a (possibly spontaneous) Schiff's base formation. CouR2a/b 
may catalyse a decarboxylation of the resulting intermediate, and the putative FMN-
dependent dehydrogenase CouR4 may oxidize the pyrroline to the pyrrole (Figure 
IV.2). However, other molecules than oxaloacetate are equally conceivable as 
precursors of this part of CPM, e.g. maleic acid, and both, feeding studies and 
biochemical experiments, are required to elucidate this biosynthetic reaction 
sequence. 
 
Feeding experiments with isotope-labeled precursors are widely used for the 
identification of biosynthetic building blocks, especially in PKS- and NRPS-derived 
compounds (Erol et al., 2010; Ohlendorf et al., 2008; Schuhmann & Grond, 2004; 
Surup et al., 2007; Weber et al., 2008). The origin of the isoprenoid moiety of 
furanonaphthoquinone I and endophenazine A from the mevalonate pathway, for 
example, was shown by feeding experiments with [13C2]acetate and [2-
13C]glycerol 
(Bringmann et al., 2007) and Bunton et al. (1963) showed that the aminocoumarin 
moiety of novobiocin is derived from L-tyrosine by feeding of [14C]L-tyrosine. 
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In the conducted feeding experiment with [U-13C,15N]L-threonine, a very strong 
(19.5 %) 13C enrichment was observed for the pyrrole carbons C-2, C-3, C-6 and C-
7. For the other carbons of CPM monoamide no significant incorporation was 
observed, except for a weak (1.8 %) enrichment for the methyl group attached to 
position 8 of the aminocoumarin ring. This methyl group is derived from S-
adenosylmethionine (SAM) (Pacholec et al., 2005b) and its labeling can be readily 
explained by the degradation of L-threonine to glycine via an aldol cleavage (Balk et 
al., 2007; Liu et al., 1998). Glycine, like serine and formaldehyde, is a carbon-donor 
for the generation of N5,N10-methylene-THF from tetrahydrofolate (THF), which in 
turn provides the methyl group of SAM (Berg et al., 2011).  
 
 
3. Identification and structural elucidation of new caprazamycins 
from Streptomyces sp. MK730-62F2 by LC/ESI-MS/MS 
 
The biosynthetic gene clusters of caprazamycins and liposidomycins, respectively, 
were recently identified by our group (Kaysser et al., 2009; Kaysser et al., 2010a). 
The heterologous expression of the caprazamycin gene cluster originally resulted in 
the production of the caprazamycin aglyca, since the genes for the biosynthesis of 
the L-rhamnose moiety are located in a second cluster elsewhere on the genome 
(Kaysser et al., 2010b). Inactivation of cpz20, cpz21 and cpz25 led to the production 
of new simplified liponucleoside antibiotics that lack the 3-methylglutaryl moiety 
(Kaysser et al., 2009) and an in vitro assay with the putative glycosyltransferase 
Cpz31, using dTDP-L-rhamnose and the caprazamycin aglyca as substrates, 
resulted in the production of 2,3,4-desmethyl caprazamycins (Kaysser, 2010). The 
identification of all these compounds required a rapid and precise analytical method 
that also supplies sufficient structural information. High-performance liquid 
chromatography (HPLC) coupled to a triple-stage quadrupole or ion trap mass 
spectrometer (MS) is capable of both, separating complex mixtures of secondary 
metabolites and providing reliable information on the analyte‟s mass and structure. 
Therefore a LC-ESI-MS/MS method for the identification of caprazamycins and 
liposidomycins in the culture extracts of the respective producer strains using a triple-
stage quadrupole mass spectrometer was established in this study. 
 
The liponucleoside antibiotics are complex compounds that contain acidic as well as 
basic functional groups. Therefore the caprazamycins and liposidomycins were 
readily detected in positive as well as in negative ionization mode. However, the 
positive mode provides more structural information and so is used for the routine 
analysis of caprazamycins and liposidomycins, respectively. However, if informations 
regarding the sulfate group or the fatty acid moiety are required the negative 
ionization mode is of advantage. The overall fragmentation pattern in positive as well 
as in negative ionization mode is consistent with the published FAB-MS data for the 
liposidomycins (Kimura et al., 1998b; Ubukata et al., 1988). 
 
Affi-Gel® boronate is a boronate-derivatized polyacrylamide gel with an affinity for 
adjacent cis hydroxyl (cis-diol) groups and is able to efficiently separate low 
molecular weight molecules such as nucleotides, nucleosides, catecholamines, 
coenzymes, and sugars (Boeseken, 1949; Higa et al., 1977; Liebich et al., 1997). At 
alkaline pH values Affi-Gel® boronate forms a cyclic boronate ester with the cis-diol 
groups, which can be cleaved by shifting the pH to an acidic value. This results in the 
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elution of the cis-diol containing compound and the regeneration of the material. The 
general principle of this method is depicted in Figure IV.3. The present study now 
showed that the caprazamycins with their modified uridine structure are also able to 
bind to the boronic acid stationary phase and that a partial purification is possible by 
the described method. Originally the caprazamycins eluted in the second washing, 
consisting of 50% (v/v) methanol. This was also observed by Dino Bullinger for some 
nucleosides, e.g. for pseudouridine, and could be prevented by reducing the 
methanol content in washing step 2 from 50 to 20% (v/v) (Bullinger, 2008). A possible 
reason for the early elution of the caprazamycins could be the occurrence of 
secondary interactions between the boronic acid gel and some other structural 
moiety, e.g. with the amino group of the aminoribose (Tuytten et al., 2007). As for the 
nucleosides a reduction of the methanol content to 20% (v/v) in washing step 2 was 
able to solve the problem. 
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Figure IV.3 
Principle of the affinity chromatography on a boronic acid gel (Affi-Gel® boronate). Modified 
from Bullinger (2008). 
 
 
Previously, 27 liposidomycin derivatives containing 13 different fatty acid side chains 
have been isolated from Streptomyces sp. SN-1061 (Esumi et al., 1999; Kimura et 
al., 1998b). In contrast, only seven caprazamycins were reported from Streptomyces 
sp. MK730–62F2 (Igarashi et al., 2005). Both gene clusters are highly conserved and 
do not contain possible genes for fatty acid biosynthesis. Consequently, the fatty acid 
moiety of the liponucleoside antibiotics is most likely provided by the primary 
metabolism of the host strain. We therefore wanted to investigate if the variety in the 
length and conformation of the fatty acid side chain known from the liposidomycins 
can also be found for the caprazamycins. In the present study we report the 
identification of at least six new caprazamycins, termed CPZ G, H, I, J, K and L. The 
mass differences of the new compounds to the known caprazamycins suggest the 
incorporation of unsaturated fatty acids and the proposed chemical formula fit that of 
the fatty acid side chains of the liposidomycins Y, Z, A, G, K and N, respectively. 
However, the exact regiochemistry of the new caprazamycins could not be 
determined with the means available. 
 
 IV. DISCUSSION 71 
 
The position of double bonds in unsaturated fatty acids can normally be determined 
by charge-remote fragmentation, a class of gas-phase decompositions that occur 
physically remote from the charge site (Adams, 1990; Adams & Songer, 1993; Gross, 
1992). Under high-energy collisional activation (CA), e.g. in sector instruments with 
fast-atom bombardment (FAB) as ionization technique, fatty acids undergo charge-
remote fragmentation to give a series of product ions, representing the cleavage of 
consecutive C-C single bonds, from which the structure of the fatty acid can be 
determined (Cheng & Gross, 2000; Hsu & Turk, 2008). At the position of a double 
bond the ion series is interrupted by a gap which is framed by two abundant ions on 
either side (Hsu & Turk, 1999, 2008). More recently, the classic fragmentation 
processes were also observed under low-energy CA, e.g. in tandem quadrupole 
instruments with electrospray ionization in negative mode, as used in the present 
study. However, these studies were mainly conducted on free fatty acid and not on 
such complex compounds as the liponucleoside antibiotics (Hsu & Turk, 1999, 2008). 
Accordingly, the structure elucidation of the fatty acid moieties of the liposidomycins 
was conducted under high-energy conditions (Esumi et al., 1999) and also no 
charge-remote fragmentation was observed for the caprazamycins under low-energy 
conditions in the present study. 
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1. MS data 
 
Figure VI.1: CID-MS/MS spectrum of coumermycin A1 
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Figure VI.2: Suggested structural formulas of the mass spectrometric fragments m/z 
206 and 232 [M-H]- 
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Figure VI.3: CID-MS/MS spectrum of coumermycin A2 
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Figure VI.4: CID-MS/MS spectrum of coumermycin B 
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Figure VI.5: CID-MS/MS spectrum of coumermycin C 
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Figure VI.6: CID-MS/MS spectrum of coumermycin D-1b/1c 
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Table VI.1 
LC-MS/MS analysis of caprazamycins (CPZ) and liposidomycin (LPM) A in positive and 
negative ionization mode 
 
Compound m/z [M+H]+ MS/MS m/z (%) m/z [M-H]- MS/MS m/z (%) 
CPZ A/B 1146,6 1146,8 (30), 1015,6 
(28), 958,5 (2), 827,3 
(100), 715,2 (10), 
558,0 (4), 427,1 (6), 
320,0 (47), 189,0 (40) 
1144,6 1144,7 (8), 1100,8 (1), 
587,0 (12), 556,3 
(<0,1), 512,2 (<0,1), 
362,7 (100), 332,8 
(42), 271,1 (1) 
CPZ C/D/G 1132,6 1132,7 (32), 1001,6 
(28), 944,4 (4), 813,3 
(100), 701,2 (10), 
558,0 (4), 427,1 (6), 
319,9 (38), 189,0 (39) 
1130,6 1130,7 (8), 1086,9 
(<1), 573,1 (17), 556,4 
(<1), 512,2 (<0,1), 
362,8 (100), 332,9 
(46), 257,1 (<1) 
CPZ E/F 1118,6 1118,7 (26), 987,6 
(28), 930,4 (2), 799,3 
(100), 687,2 (9), 557,9 
(4), 427,0 (6), 320,0 
(46), 189,0 (46) 
1116,6 1116,7 (4), 1072,9 
(<1), 559,0 (10), 556,0 
(<0,1), 512,4 (<0,1), 
362,9 (100), 333,0 
(27), 243,0 (<1) 
LPM A 1034,4 1034,3 (<0,1), 954,7 
(38), 823,5 (100), 
711,4 (11), 558,2 (1), 
427,1 (8), 315,1 (3) 
1032,4 1032,3 (63), 988,5 
(<1), 952,4 (<0,1), 
635,9 (2), 592,0 (100), 
556,0 (1), 395,1 (<1), 
362,8 (<0,1), 267,0 
(1), 144,9 (<1) 
 
 
 
 
Table VI.2 
Molecular formulae of caprazamycins A-M and calculated molecular weights 
 
Caprazamycin Molecular formula R (unsaturation) Molecular weight 
A/B C53H87N5O22 C13H27 (0) 1146 
C/D/G C52H85N5O22 C12H25 (0) 1132 
E/F C51H83N5O22 C11H23 (0) 1118 
H C51H79N5O22 C11H19 (2) 1114 
I C51H81N5O22 C11H21 (1) 1116 
J C53H83N5O22 C13H23 (2) 1142 
K C53H85N5O22 C13H25 (1) 1144 
L C55H87N5O22 C15H27 (2) 1170 
M C55H89N5O22 C15H29 (1) 1172 
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2. NMR data 
 
 
Calculation of 13C enrichment after feeding of [U-13C,15N]L-threonine 
 
 
[U-13C,15N]L-threonine was purchased with 99% enrichment. 
 
13C enrichment in the isolated CPM monoamide was calculated as described by 
Scott et al. (1974) 
 
1.1
][
][
1.1[%] 
unlabeledI
labeledI
enrichment  % 
 
Integrals of coupling signals of carbon atoms were calculated as the sum of the 
integral of the full multiplets. Carbon C-9‟ of the coumarin moiety was used as the 
non-13C-enriched internal reference signal. 
 
Integrals for singlet signals of respective carbon atoms were calculated using the 
integral of the central line (ICL) of the multiplets and the usual singlet signals. Only 
carbon C-11‟ turned out to be enriched (see Main Text, Table 2). 
 
1.1
][
][
1.1[%] 
unlabeledI
labeledI
enrichment CL  
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Figure VI.7: 1H-NMR spectrum of unlabeled CPM monoamide (400 MHz, d6-DMSO); 
Signal assignments are shown in Table VI.3 
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Figure VI.8: 13C-NMR spectrum of unlabeled CPM monoamide (100.6 MHz, d6-
DMSO); Signal assignments are shown in Table VI.3 
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Figure VI.9: H,H-COSY of unlabeled CPM monoamide (600 MHz, d6-DMSO); 
selected correlations are shown in Figure VI.12. 
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Figure VI.10: HSQC of unlabeled CPM monoamide (600 MHz, d6-DMSO); selected 
correlations are shown in Figure VI.12. 
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Figure VI.11: HMBC of unlabeled CPM monoamide (600 MHz, d6-DMSO); selected 
correlations are shown in Figure VI.12. 
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Figure VI.12: Selected 1H-1H-COSY (↔), HSQC (→) and HMBC (-----) correlations 
from 2D NMR experiments for unlabeled CPM monoamide (600 MHz, d6-DMSO) 
 
 
 
 
 
Table VI.3  
Assignment of 1H and 13C NMR signals of unlabeled CPM monoamide 
 
Position  
 
1H-NMR data 
(600 MHz, d6-DMSO) 
δH [ppm] 
13C-NMR data 
(125.7 MHz, d6-DMSO) 
δC [ppm] 
1 11.85, 1H, bs, NH  
2 - 120.6 
3 - 127.8 
4 - 118.0 
5 7.73, 1H, d, J = 2.8  125.5 
6 12.50, 1H, bs, COOH 162.4 
7 2.50, 3H, s, CH3 011.2 
8 - 160.9 
9 11.95, 1H, bs, NH  
1„ -  
2„ - 164.8 
3„ - 100.5 
4„ 10.47, 1H, s, OH 159.3 
5„ 7.57, 1H, d, J = 8.7  121.5 
6„ 7.90, 1H, d, J = 8.7  111.9 
7„ 8.89, 1H, s, OH 158.9 
8„ - 110.3 
9„ - 151.2 
10„ - 108.3 
11‟ 2.16, 3H, s, CH3 008.1 
bs = broad signal 
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Figure VI.13: 1H-NMR spectrum of coumermycin A1 (400 MHz, d6-DMSO) 
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Figure VI.14: 13C-NMR spectrum of coumermycin A1 (100.6 MHz, d6-DMSO) 
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Figure VI.15: 1H-NMR spectrum of 3-methylpyrrole-2,4-dicarboxylic acid (250 MHz, 
d6-DMSO). 
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